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ABSTRACT
The rodent model is often used to study the impact of dietary n-3 fatty
acids on a variety of biological endpoints, and the results of these studies have
been used to explain anticipated effects of n-3 fatty acid intake in humans.
However, supplemental levels of n-3 fatty acids that are commonly used in
rodent studies do not represent reasonable human intake, by comparison.
Currently there is no standard method for the addition of n-3 fatty acids to rodent
diets. We tested a mathematical model for dosing supplemental levels of a
linolenic acid (ALA) and eicosapentaenoic acid (EPA) to rodent diets on the basis
of energy%. C57BI/6J mice were fed a background diet that modeled typical
Western intake in both macronutrient and fatty acid composition. Three levels of
ALA and EPA (0.3, 0.8, and 1.4 energy%) were supplemented to either a normal
ALA control diet (0.6 energy% ALA) or a high-ALA control diet ( 1.2 energy%
ALA). Plasma and erythrocyte phospholipid fatty acid changes were determined
and compared to archival human n-3 fatty acid supplementation studies reporting
the same tissue endpoints. In mice, supplemental EPA had a greater effect than
supplemental ALA on both plasma and erythrocyte phospholipid EPA.
Docosahexaenoic acid (DHA) levels in mice were only minimally changed by
either ALA or EPA supplementation. Use of the high- ALA control diet resulted in
attenuated phospholipid fatty acid changes in both tissues compared to the
normal-ALA control diet for both supplemented fatty acids. At each
supplemented dose of ALA or EPA, changes in murine plasma or erythrocyte
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phospholipid EPA exceeded changes observed in the same human tissues by
2-4 fold when compared to equivalent human supplemental doses in energy%.
Tissue changes observed using the high-ALA control diet better modeled the
results observed in humans at the same supplemental energy% for both ALA and
EPA in plasma and erythrocyte phospholipids. This is the first study to use
pharmacodynamic modeling to compare the effect of supplemental n-3 doses on
mouse and human endpoints. The addition of n-3 fatty acids to rodent diets on
the basis of energy% represents a reasonable improvement to current dosing
strategies. This data is useful both as a guideline for n-3 fatty acid dosing in
rodent studies and as a reference point for future calculated refinements in
dosing.
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1

REVIEW OF THE LITERATURE

1.1

Introduction
The generation of information regarding omega-3 (n-3) fatty acids has

been prolific over the past thirty years subsequent to Dyerberg and Bang's
discovery in 1 971 attributing heart disease incidence reduction in Greenland
Eskimos to their consumption of polyunsaturated fatty acids, particularly n-3 fatty
acids (1 -3). Data obtained from both animal studies and human clinical trials
have been used to examine the mechanisms by which n-3 fatty acids convey
health benefits and to make judgments about optimal dietary intake levels for
general health and disease prevention. Although much knowledge has been
gained, there are still several questions that have not been fully addressed. The
following project grew out of a need for empirical data to address three primary
questions:
1 . What is the difference in biological impact between terrestrial n-3 fatty
acid, cx-linolenic acid (1 8:3 n-3; ALA), and long- chain n-3 fatty acids
(LCn3), eicosapentaenoic acid (20:5 n-3, EPA) and docosahexaenoic acid
(22:6 n-3, DHA)?
2. What is the impact of terrestrial or LCn3 in mice when given at levels that
are comparable to human supplemental intake?
3. What methodological improvements can be made in the dosing of n-3 fatty
acids in rodent studies that allows for a more direct comparison of mouse
and human data and a standardization of dosing across different research
studies using animals?
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1.2

Overview of Omega-3 Fatty Acids

Description
N-3 fatty acids are polyunsaturated hydrocarbon chains in which the first
double bond occurs at the third carbon from the methyl end of the molecule (4).
The three predominant dietary n-3 fatty acids are: ALA, EPA, and DHA (Figure
1-1). The unique structure of n-3 fatty acids predicts, in part, their biological fate.
Methylene-interrupted double bonds present within n-3 fatty acids make them a
vulnerable target for hydrogen abstraction by reactive oxygen species due to
both weakened carbon-hydrogen bonding at the methylene groups and to
structural potential for radical stabilization via resonance (4 ).

Dietary sources
ALA is an n-3 fatty acid of plant origin that is consumed primarily in the
form of vegetable oils such as canola oil (9.3% ALA by weight) and soybean oil
(6.8 % ALA by weight) (5). Other significant sources of ALA include walnuts,
flaxseeds, flaxseed oil, soybeans, soybean oil, and wheat germ (Table 1-1). EPA
and DHA are often called the "marine" n-3s because they are present in the
highest concentration in fatty fish such as mackerel, herring, salmon, tuna, trout,
and halibut (6). There are also a variety of oil capsule supplements on the
market that contain varying concentrations of EPA and DHA (and !n some cases,
other polyunsaturated fatty acids as well).

3

CHaCOOH

18: 3 n-3, exrUnoleric acid

H3
20:5 n-3. Eicosapentaenoic acid

22: 6 n-3, Docosat-exaenoic acid
Figure 1-1: Structure and nomenclature of the three predominant n-3 fatty acids
· found in the Western diet.

Table 1-1

Alpha-linolenic acid content of selected food sources (5).

Food Source

ALA content (wt%)

Canola oil
Flax seeds
Flax seed oil
Soybeans
Soybean oil
Walnuts (English)
Wheat Germ

9.3
1 8.1
58
1 .3
6.8

9.1
0.72
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Western consumption
Kris-Etherton, et al. (6) report that the average daily intake of all n-3 fatty
acids in the United States is-1.6 grams (or 0.7 energy% based on a 2000
calorie diet). The average U.S. consumption of ALA is 1.1-1.4 grams per day
(0.5-0.6 energy%) (6, 7). Soybean oil and canola oil are the most prevalent ALA
sources in the U.S. diet (6). The remaining portion of average daily n-3 intake
comes from roughly 75 mg EPA and 125 mg DHA for a total of-200 mg LCn3
(0.09 energy%) (6-8). According to the 1999-2000 National Health and Nutrition
Examination Survey data, the most frequently consumed fatty fish in the United
States were tuna and salmon (9, 10).

Recommendations for consumption
At present, there is insufficient data necessary to establish a Recommended
Dietary Allowance for ALA, EPA and DHA; however, several dietary
recommendations have been made by a variety of national and international
health organizations (Table 1-2). Recommendations are generally subdivided by
the following population groups: healthy adults, pregnant mothers, and coronary
heart disease patients. In September of 2004, the United States Food and Drug
Administration (FDA) approved a petition requesting a qualified health claim for
foods containing EPA and DHA for the prevention of coronary artery disease
(11).

TABLE 1-2 1
Selected national and international omega-3 fatty acid recommendations.
AGENCY/GROUP

COUNTRY

POPULATION GROUP

RECOMMENDATION

American Heart
Association (12)

USA

Adults

Two servings fatty fish/ week
Include oils rich in ALA

CHO patients

-1 g EPA + DHA/ day

Patients with i TG

2-4 gms EPA+ DHA/ day

Adults

ALA: 2.22 g/day
EPA to be at least: 0.22 g/day
DHA to be at least: 0.22 g/day

Pregnancy/ Lactation

DHA to be at least: 0.3 g/day

Workshop on the
Essentiality of and
Intakes from Omega-6
and Omega-3 Fatty
Acids (13)

Intemational

International
Society for the
Study of Fatty
Acids and Lipids (14)

International

Adults

ALA: 0.7 energy%
(1.56 g/day; 2000 kcal)
EPA+ DHA: at least 0.5 g/ day

World Health
Organization (15)

International

Adults

All co-3 fatty acids: 1-2 energy%
(2.2- 4.4 g/day; 2000 kcal)

0,

0)

TABLE 1-2 1
Continued

AGENCY/GROUP

COUNTRY

POPULATION GROUP

RECOMMENDATION

National Heart Foundation
of Australia (16)

Australia &
New Zealand

Healthy adults and CHO patients

ALA: 2 g/day
At least 2 fatty fish meals/week

Nordic Council of
Ministers (17)

Denmark, Finland,
Norway, & Sweden

Persons over 3 years of age

All co-3 fatty acids: At least 0.5%
(1.1 g/day; 2000 kcal)

British Nutrition
Foundation (18)

United Kingdom

Adults

Health Council of the
Netherlands (19)

The Netherlands

Birth to 5 months

ALA: 0.08 g/ kg/day
DHA: 0.02 g/ kg/ day

Adults

ALA: 1.0 energy%
(2.2 g/day; 2000 kcal)
EPA+ DHA: 0.2 g/ day

Pregnancy & Lactation

ALA: 1.0 energy%
EPA+ DHA: 0.2 g/day

1

Adapted from Source: (20).

ALA: At least 0.2 energy%
(0.44 g/day; 2000 kcal)
EPA+ DHA: 0.5 energy%
(1.1 g/day; 2000 kcal)
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It reads,

"Supportive but not conclusive research shows that consumption of EPA
and DHA omega-3 fatty acids may reduce the risk of coronary heart
disease. One serving of [Name of the food] provides [ ] gram of EPA and
DHA omega-3 fatty acids. [See nutrition information for total fat, saturated
fat, and cholesterol content.]"
The use of this health claim will help to encourage public consumption of LCn3
and increase the likelihood of reaching intake recommendations.

Digestion, absorption, and transport
N-3 fatty acids are consumed in the form of triglycerides and
phospholipids present in food. Phospholipids contain 85-90% fatty acids and
triglyceride content is -95% fatty acid (21 ). As unsaturated fatty acids, ALA, EPA
and DHA are primarily found in the sn-2 position of both triglycerides and
phospholipids (22). N-3 fatty acids follow the same course of digestion and
absorption as other lipid components. The mechanical churning of the stomach
(coupled with the action of gastric lipase) is the first step in lipid digestion (22).
Some short and medium chain fatty acids are directly absorbed through the
stomach wall. Longer fatty acids (all omega-3s), however, are primarily broken
down in the small intestine. In the duodenum, bile salts from the liver, as well as
physical hydrophobic interactions (23), help to emulsify fat droplets into
manageable subsections, creating an increase in surface area for enzymatic
action. Pancreatic lipase (activated by co-lipase) hydrolyzes fatty acids in the
sn-1 and sn-3 positions on the glycerol backbone of food derived triglycerides
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(24), leaving two non-esterified fatty acids and 2-monoacylglycerol.
Phospholipase A2 , also originating in the pancreas, cleaves fatty acids present in
the sn-2 position of phospholipids, leaving a free fatty acid and a
lysophospholipid (22) (Figure 1-2). The free fatty acids and partially digested
acylglycerols and phosphoglycerols are transported through the hydrophilic layer
that coats the intestinal lumen by micelles. Micelles are small groupings of
phospholipids, free fatty acids, cholesterol, mono and diacylglycerols, and bile
salts that act as amphipathic carriers of lipid soluble molecules to the enterocyte
membrane surface.

Trig lycerlde

Phosphollpld

Pancreatic Li pase activity
Phosphol i pase � activity

Figure 1-2: Targeted bo.nds of pancreatic lipase _on dietary triglyceride and
phospholipase A2 on dietary phospholipids.

9

Particles of lipid digestion were at one time thought to be absorbed solely
via passive diffusion, however, it is now believed that fat binding protein carriers
help to mediate the transfer (25, 26). Within the enterocyte, fatty acids,
monoacylglycerols and phosphoglycerols are reassembled into triglycerides and
phospholipids and combined with apoprotein to be secreted into the lymphatic
system as chylomicrons and eventually enter circulation through the superior
vena cava. Chylomicrons are distributed in the circulation to adipose tissue for
storage and other peripheral tissues for energy (22). Lipoprotein lipase attached
to the endothelial wall of tissue capillaries cleaves the fatty acids in the sn-1 and
sn-3 positions of triglycerides, in a similar fashion to pancreatic lipase.
Monoacylglycerol lipase within the plasma membrane finishes the hydrolysis of
2-monoacylglycerol (27) and the fatty acids are carried across the membrane via
a fatty-acid binding protein that co-transports with sodium ions (22). Free
glycerol and chylomicron remnants are circulated back to the liver and absorbed.
The metabolic fate of absorbed fatty acids depends on the tissue, the fatty acid
type, and the energy state of the individual .

Endogenous long chain omega-3 formation
In addition to dietary intake, a minor amount of long chain n -3 fatty acids
are synthesized de novo from dietary ALA (Figure 1-3). Mammals lack the
ability to desaturate fatty acyl chains beyond the Li9 carbon, making consumption

10

Ei cosatetraenoic aci d (20:4 n-3)

EPA

Eicosapentaenoi c acid (20: 5 n-3)

Docosapentaenoic aci d (22:5 n-3)

Tetracosapentaenoic acid (24:5 n-3)

rI
!

DHA

i

Tetracosahexaenoi c aci d (24 : 6 n-3)

t

'V
:

I:

Peroxisomal
retro-conversion

_________)

I I

Docosahexaenoic acid (22: 6 n-3)

\,__

Figure 1 -3: Enzymatic conversion of ALA to LCn3 metabolites. Conversion
occurs on the cytosolic interface of the endoplasmic reticulum with the final two
steps involving peroxisomal retroconversion (28-31).
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of the parent compound ALA essential (32). Conversion of ALA to long chain
metabolites takes place using enzymes found in the endoplasmic reticulum
membrane (29-3 1 ) (examined as microsomes), with the final steps of DHA
synthesis using peroxisomes (28). The majority of conversion takes place in the
liver, however, the machinery for ALA desaturation has been found in a variety of
tissues such as brain, skeletal muscle , lung, and heart (33, 34). Table 1 -3
compares several studies where ALA conversion rates were estimated using oral
doses of radio-labeled ALA. Most studies report less than 5% conversion from
ALA to EPA, and overall there appears to be very little conversion to DHA. This is
supported by a study reporting an inverse relationship between the amount of
dietary ALA consumed and DHA in several blood fractions (35). It was
suggested that ALA is displacing DHA from membrane PLs, which would result in
decreased absolute DHA content in the membrane. The highest conversion
rates were seen in a study by Burdge et al. (36), where the rate of ALA to EPA
conversion in young women was 21 % and the conversion to DHA was 9%.
Separating conversion rates by gender has led to the hypothesis that women
may have a greater potential for conversion based on childbearing capacity and
prenatal needs for DHA (36, 37).
Several factors influence the propensity for ALA conversion to long chain
metabolites, including:
•

The amount of ALA at a given time that is removed from conversion
by �-oxidation (38).

TABLE 1-3
Comparison of estimated metabolic conversion rates of dietary a-linolenic acid to long chain metabolites.

Author/ Source

Subjects

Background
Diet

Emken (39), 1994

Young adult males

LA- 15 g/d

Labeled fatty acid

Percent
Conversion to
EPA

Percent
Conversion to
DHA

Deuterated

8.0 ± 1.5

4.0 ± 1.6

3.4 ± 0.5

3.6 ± 2.0

LA + ALA

LA- 30 g/d
Hoffman (40), 2001

Healthy males

Low fat
Low omega-3

Pawlosky (38), 2001

Healthy adults

Beef based

Pawlosky (41), 2003

Healthy adults

Self selected

C
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5.0

ALA

Pentadeuterated

0.2 ± .02

0.047

Pentadeuterated

0.2 ± 0.01

0.057

Fish based

0.10 ± 0.02

0.018

Beef based

0.19 ± 0.01

0.075

ALA

ALA

TABLE 1-3

Continued
Percent
Conversion to
EPA

Percent
Conversion to
DHA

Author/ Source

Subjects

Background
Diet

Burdge (42), 2002

Young men

Habitual diet

C

ALA

7.9

0

Burdge (36), 2002

Young women

Habitual diet

C 1 3 ALA

21

9

Burdge (43), 2003

Older men

Control

C

1.96 1

0.031

ALA- 10g/d

2.61

0.051

EPA+ DHA- 1 . 5 g/d

4 . 01

0.071

1

Labeled fatty acid
13

13

ALA

Based on cumulative amounts of EPA or DHA as a percent of total labeled ALA + EPA + DPA + DHA.
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•

The rate and sufficiency of desaturase enzymes (Ex: Li-5
desaturase down regulation in retinitis pigmentosa (40)).

•

The amount of linoleic acid (LA; 18:2n-6) in the diet (39, 44 ). LA
competes with ALA for the rate limiting Li-6 desaturase enzyme.
Delta-6 desaturase is 19 times more selective for ALA than for LA
(45), however, the ratio of LA content to ALA content in the typical
Western diet is 10: 1, thus presenting competitive inhibition of ALA
conversion.

•

The absolute amount of ALA, EPA, and DHA in the diet (46-48).

One limitation of current conversion studies is their reliance on plasma
data. It is arguable that in tissues where DHA is particularly important (i.e. brain
and retina), conversion rates may be greater to compensate for insufficient
dietary DHA, and that this is not reflected in the conversion estimations from
plasma. However, overall, the current estimates of ALA conversion suggest that
dietary ALA intake may not be a sufficient substitute for preformed LCn3 (39),
particularly if the benefits associated with LCn3 intake are desired. Furthermore,
increasing ALA consumption from food sources in an attempt to maximize ALA
conversion may yield a level of total fat intake that exceeds current dietary
recommendations (49).
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Critical location and timing of accumulation
The chief residence of n-3 fatty acids in biological organisms is the sn-2
position (50 , 51 ) of phospholipids that compose cellular and organelle
membranes. Polyunsaturated fatty acids are usually found within phospholipids
on the cytosolic half of the membrane bilayer (52). ALA, DHA, and EPA can all
be found in membranes, however, ALA is almost negligible in membrane lipids
(Table 1 in (53) & (54)) due to its propensity to be oxidized or used for other
metabolic purposes including its use a precursor to the other n-3 acids as
described above. The most prominent membrane n-3 is DHA followed by DPA
and EPA (Table 1 in (53)). The two tissues that accumulate the highest
concentration of n-3 fatty acids in the body are retinal photoreceptor rod outer
segments (53) and neural synaptosomes (49). DHA makes up 50% of the fatty
acid content of rod outer segment membrane in the retina and can occupy both
the sn-1 and sn-2 positions of the these phospholipids (55), allowing for maximal
DHA concentration. Most of the DHA found in brain and retina accumulates in
the last trimester of pregnancy and the early part of life after birth (50, 56-58).
Prenatal accumulation of LCn3 is complex and involves several possible
contributing sources. Maternal blood supply to the fetus (via the placenta) is the
main supply of all fatty acids to the growing infant and lipid transfer is a reflection
of maternal diet as well as maternal lipid stores (50, 59). Placental specificity for
DHA binding has been reported (60), highlighting the priority that is placed on
DHA acquisition for the fetus. Fetal conversion of ALA to LCn3 offers another
possible route for accumulation. Conversion has been reported in fetal brain (56,
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61 ) and liver (51 ) . Delta 5 and �6 desaturase enzymes have also been found in
human placenta (33). Lastly, it has been shown in rats that amniotic fluid
swallowed in utero may also provide ALA to the fetus as a LCn3 precu rsor (51 ,
62).
In the initial period after birth , the infant is dependent on both body stores
and external feeding for n-3 fatty acids. Breast milk is rich in DHA and AA (63).
Synthetic formu las, however, were devoid of either fatty acid u ntil 2002, when
commercial formula companies began adding DHA and AA to their formula in an
attempt to better mimic breast milk (64 ). Infants receiving formula without DHA
are dependent on conversion from ALA in formula or adipose stores to obtain
necessary DHA. Both term and preterm infants can convert ALA to DHA (65),
however, this sou rce of LCn3 is limited . Rat pup body stores of DHA have been
shown to be a substantial source of DHA in rat brain (66), even when ALA is
provided in the diet, suggesting that there is a preference for preformed D HA.
This is a particularly important discovery for the treatment of preterm infants (66),
who may miss the adipose accu mulation associated with the later stages of
gestation (67, 68) resulting in a reduced reserve of DHA from adipose.
Brain and retina are known to protectively retain DHA content (50, 69),
and both are resistant to dietary n-3 deprivation (53, 70). Other membranes that
are less dependent on stable n-3 fatty acid content such as liver, erythrocyte, and
plasma membranes, readily undergo fatty acid turnover that is a directly
influenced by changes in dietary intake .
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Functional use of omega-3 fatty acids in the body

Function derived from structure
EPA in plasma membranes is mainly used as an eicosanoid precursor
(see below), while DHA in membranes has a very specific structural function.
The six double bonds of DHA impart flexibility (71 , 72), disorder (73), and free
volume (74) to regions of high DHA concentration. Steric hindrances and
neighboring molecules exert external forces on the acyl chains (55) of
phospholipid molecules, influencing the thermodynamic favorability of different
structural conformations within the membrane. Molecular simulations show that
DHA is able to make rapid conformational changes (72), and "interconversion
between torsional states" (73, 75), and this is how it is able to confer acyl chain
flexibility and fluidity to membranes. The space and flexibility provided by DHA
content impacts the activation of certain membrane embedded receptors and
enzymes, particularly those that undergo conformational changes upon activation
requiring space for expansion.
In the rod outer segments of the retina, high DHA concentration
facilitates the activation of rhodopsin and subsequent G protein-coupled receptor
signaling that impacts the visual response (76). Anderson, et al. (77) have
shown that the retina conserves DHA because of its importance in rhodopsin
activation. In the event of n-3 deficiency, 22:5 n-6 accumulates in the retina in
place of DHA (76, 78). However, even though 22:5 n-6 is almost structurally
identical to DHA in that it lacks only 1 double bond , DHA replacement negatively
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impacts electroretinogram measurements, implying that DHA provides a specific
structural advantage for rhodopsin activation and vision (78).
The structural influence of membrane DHA on G protein-coupled
receptors may also effect the neurotransmission of dopamine, serotonin,
norepinephrine, acetylcholine, and GABA; all of which use G protein coupled
receptors (53). This is plausible based on the high concentration of DHA in
synaptosmal membranes and the repeated observation that DHA concentration
may affect psychological outcomes. It has also been shown that
neurotransmitter reuptake may be increased by degree of membrane
unsaturation (79) through enhancement of pinocytosis.
Ion channels and transport proteins are also affected by n-3 fatty acid
content in the membrane. DHA has been shown to influence potassium
+

+

+

channels (80), Na K -ATPase activity (81, 82), and EPA influences Na and
++

Ca

channels in cardiac myocytes · (83, 84).
Some of the other structural characteristics that are influenced by the DHA

content in the membrane include:
•

Lipid rafts- Lack of affinity between DHA rich regions and cholesterol
cause cholesterol rich/ DHA poor domains to form laterally within the
membrane (85). Formation of lipid domains compartmentalize portions of
the membrane for specific functions (32). Raft formation may also
influence membrane embedded protein localization (73).

•

DHA influences the speed of phospholipid flip-flops across the
hydrophobic region within the plasma membrane(86).
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•

DHA may also intercept oxidative damage that would otherwise affect
receptors and other membrane proteins (53).

Function derived from biological products

Polyunsaturated fatty acids (ex: DGLA (dihomogammalinolenic acid), AA,
EPA, and DHA) are precursors to a diverse host of biological products including:
prostaglandins, leukotrienes(87), thromboxanes, lipoxins(87, 88), hepoxilins,
hydroxy and hydroperoxy compounds (89); and the more recently discovered:
isoprostanes (90, 91 ), neuroprotectins (92), and resolvins (93). AA and EPA
are the two main eicosanoid precursors which compete for sn-2 position
placement in membrane phospholipids and subsequent cleavage for ultimate
eicosanoid production. Phospholipid concentration of AA and EPA is a direct
reflection of dietary intake (89). AA and EPA are substrates to several enzyme
systems that produce eicosanoid products, such as: cyclooxygenases (COX),
lipoxygenases (LOX), and epoxygenases (32, 94 ). Eicosanoids act as local
hormones (23), having both autocrine and paracrine activities; they travel only
short distances to their site of action (32, 95). This is, in part, due to their rapid
inactivation and metabolism (96, 97). AA is a precursor to the series-2
prostaglandins (ex: PGE2, PGl2, TXA2) and the series-4 leukotrienes (ex: LTA.t,
LTB4 , etc . . ). EPA is a precursor to the series-3 prostaglandins (ex: PGE3, TXA3)
and the series-5 leukotrienes (ex: LTAs, LTB5 ). In general, products derived from
EPA are less potent and exhibit a less inflammatory effect than products derived
from AA (97). For example, platelets produce the AA derived product
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thromboxane A2 , which acts as a vasoconstrictor and stimulates platelet
aggregation (98). If EPA is enriched in membrane phospholipids rather than AA,
EPA will be released and used to produce thromboxane A3 , which is neither a
strong vasoconstrictor or aggregator (Figure 1 -4) (98). Enrichment of
membranes with EPA as a competitor to AA has been suggested for the
amelioration of several pathological conditions where AA derived products elicit
undesirable effects, such as: rheumatoid arthritis, asthma , cancer, thrombosis,
and other conditions involving n-6 eicosanoid stimulated inflammation.
In addition to the competitive effect between EPA and AA for enzymes
involved in eicosanoid production, new research indicates that EPA and DHA are
precursors to potent derivatives of their own, namely, neuroprotectins (92) and
resolvins (93). Resolvins (short for "resolution phase interaction products") are
produced from both EPA and DHA and have been shown to have anti
inflammatory properties through their involvement with polymorphonuclear
leukocytes (93). Neuroprotectins are derived from DHA and are believed to
protect brain cells from oxidative stress-induced apoptosis" (92).
11

Function derived from genetic influence
In addition to their structural and eicosanoid functions, n-3 fatty acids have
been shown to have substantial influence on gene expression (99). Omega-3
fatty acids act as ligands to several nuclear transcription factors involved in
metabolism, such as: peroxisome proliferator activated receptors (PPAR-a , -�,
and -y), liver X receptors (LXR-a and LXR-�), and the retinoic X receptor (RXR)
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EPA

AA

PG H 3

TXA3 :

Weak Constrictor,
Aggregator

TXB 2 :

Vasoconstrictor,
Aggregator

Figure 1 -4: Eicosanoid derivatives of EPA or AA in stimulated platelets; Series-2
vs. Series-3 thromboxanes (98, 100).
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(101-103). N-3 fatty acids have also been shown to influence (101) other
transcription factors, namely, sterol regulatory binding proteins (1a, 1c, & 2) (104,
105), nuclear factor Y (106), and hepatic nuclear factor-4 (107) (though not
through ligand binding). The net effect of PUFA genetic influence (101) is an
increase in the expression of enzymes involved in �-oxidation (108) [ex: acyl CoA
oxidase (109, 110), carnitine palmitoyl transferase (111, 112), and microsomal
CYP4A2 (110)] and a decrease in the expression of several lipogenic enzymes
(108) [ex: fatty acid synthase (111, 113-115), acetyl- CoA carboxlase (110, 114),
stearoyl -CoA desaturase (113, 116), and malic enzyme (111, 113)] (Figure
1 -5). Fatty acids are believed to effect several levels of gene expression
including: transcription factor binding, mRNA stability, transcription rate, and
alteration of translation products (99) [ex: nuclear factor Y(106)]. Both n-3 and
n-6 fatty acids impact genetic expression; however, Berger et al. (117) were able
to show, specifically, that n-3 fatty acids from fish oil lead to increased expr�ssion
of genes favoring oxidation and decreased expression of genes favoring
lipogenesis based on microarray measurement. Gene expression does not
appear to be limited to LCn3. In rat brain, ALA, EPA, and DHA were shown to
have similar influence on affected genes (118). In addition to the fatty acid effect
on gene expression, eicosanoid products of PUFA are also a potential source of
influence (119, 120). Mechanisms of n-3 fatty acid effect on gene expression
are still being discovered and new findings will help to clarify what health benefits
attributed to n-3 fatty acids are due to their genetic influence.
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Figure 1 -5: Net effect of polyunsaturated fatty acid influence on several nuclear
transcription factors involved in lipid metabolism (101, 103, 12 1 ).
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Benefits of dietary omega-3 fatty acids in humans

Cardiovascular health
Omega-3 fatty acids have been studied in conjunction with several
cardiovascular health outcomes, with particular interest given to triglyceride
reduction and sudden cardiac death.

General CVD outcomes
Omega-3 fatty acids have been shown to provide benefit in the risk
reduction of several cardiovascular events and subpopulations. Fish intake and
LCn3 intake has been shown to reduce the primary risk of all cause mortality
(122, 123), coronary heart disease (123-125), and death due to cardiovascular
disease (124, 126). Fish intake and LCn3 supplementation has been shown to
provide secondary risk prevention of all cause mortality (127), death due to
coronary heart disease (127, 128), non- fatal cardiovascular events (128, 129),
and blood pressure reduction (129, 130). Dietary and supplemental ALA intake
has also been implicated in the primary risk reduction of non-fatal myocardial
infarction (131, 132), prevalence of coronary heart disease (133, 134), all cause
mortality (134 ), and death from cardiovascular disease (131, 134). Secondary
prevention from ALA intake and supplementation provided risk reduction for
coronary deaths (� 35, 136), non-fatal myocardial infarction (128, 135, 136), and
all cause mortality (136). In general, however, CVD benefit from ALA
consumption is less definitive than LCn3 consumption (137). Along with
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dietary and supplemental intake of n-3 fatty acids, the concentration of n-3 fatty
acids in serum cholesterol esters and plasma phospholipids has been shown to
provide risk reduction for fatal CHO (1 38, 1 39) and all cause mortality( 1 39).
Not all studies , however, proved beneficial . Several studies reported no
CHO reduction from ALA intake ( 1 40, 1 4 1 ) or LCn3 intake (1 42-1 44) or benefit in
risk of restenosis from LCn3 (1 45), with one study even showing an increased
risk in all cause mortality in those patients encouraged to increase fish
consumption (1 46). Kris-Etherton ,et al. attribute some of the inconsistency of
outcomes across these studies to differences in the way cardiac events were
defined , differences in the populations studied , differences in the measurement
of fish intake, or simply variability in study design (1 47).

Stroke
The effect of omega-3 fatty acids on risk of stroke remains unclear. The
etiology of this connection is also unclear, though the anti-thrombotic potential of
LCn3 (via a shift in eicosanoid prod uction) is likely a contributing factor. Several
studies report a decreased risk based on fish intake or supplemental EPA + OHA
(1 23, 1 48, 1 49), with one study showing an impact divide in gender with no effect
in men , but a reduction in stroke risk in women who ate fish at least once per
week (1 42). ALA intake has also been shown to decrease stroke risk (1 32, 1 35,
1 40). On the contrary, many studies have also reported either no benefit from
fish intake ( 1 43, 1 50) or a trend toward an increased risk of stroke based on fish
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intake (1 50) or supplementation with EPA + DHA (1 51 ) or EPA + gammalinolenic acid (1 8:3 n-6, GLA) (1 29).

Sudden cardiac death and arrhythmias
The most consistent and sound correlation between the intake of n-3 fatty
acids and cardiovascular health benefit is their effect on sudden cardiac death
and cardiac arrhythmias. The precise mechanism by which n-3 fatty acids exert
their effect on arrhythmias is not completely understood, however, the current
body of evidence centers around two main hypotheses. The first explanation is
related to the ability of polyunsaturated fatty acids to modify the electrophysiology
of heart muscle cells. N-3 fatty acids increase the threshold for heart muscle
action potential and subsequent contraction through their effect on myocyte ion
+

+

channels (both Na and Ca2 ), and this may in part explain their ability to provide
stability and anti-arrhythmic benefit to the heart (83, 84). Another possible
mechanism is specifically the dietary modification of myocyte phospholipid fatty
acid composition by n-3 fatty acids which replaces AA in the myocyte membrane
and shifts the potential away from the production of series-2 eicosanoids to
series-3 eicosanoids (1 52). This has been shown to reduce arrhythmia and
sudden cardiac death through the reduction of series-2 eicosanoid thromboxane
A2 (1 53). The majority of both observational studies and intervention studies
found a decrease in sudden death with LCn3 intake from diet (1 22, 1 25, 1 54,
1 55) or supplementation (1 28, 1 51 ). Several studies also showed that ALA
consumption is related to a reduced risk of sudden cardiac death (1 28, 1 32, 1 35,
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1 36). One study reported a relative increase in sudden death based on advice to
consume fish or fish oil capsules (1 56), however, this is an exception.

Blood triglyceride reduction

EPA and DHA (1 57) are consistently shown to reduce circulating
triglyceride levels by 1 0-33% (1 58). Several mechanisms are believed to be
involved in this reduction, including: a decrease in hepatic triglyceride synthesis
via reduction of activity in enzymes involved in fatty acid and triglyceride
synthesis; decreased secretion of triglyceride from the liver as VLDL; and an
increase in peripheral lipoprotein lipase which results in an increase in
triglyceride clearance from the blood (1 59- 1 6 1 ). Fasting plasma triglyceride
levels greatly effect the post-prandial rise in triglyceride concentration (1 60) and
potential decrease with dietary n-3 fatty acid consumption, with higher basal
triglyceride levels resulting in a greater potential reduction (1 58). Though
triglyceride level itself has not emerged as a consistent independent risk factor
for CVD, it has been suggested that the interdependent nature of triglyceride,
LDL, and HDL as lipid carriers may mask the independent role of triglyceride
levels (1 60). Increased dense LDL levels (1 62) and reduced HDL levels (1 63),
both risk factors for CVD, are partially dependent on triglyceride levels and may
actually prove a concurrent or secondary event to elevated triglyceride levels.
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Cardiovascular summary

Though results and significance vary, it is generally accepted from many
large studies that n-3 fatty acid intake (particularly LCn3) offers a beneficial effect
through the reduction of specific cardiovascular health outcomes such as CVD
mortality, sudden death (cardiac arrest), and myocard ial infarction (1 37). It is
also noteworthy that although the results of studies using LCn3 or ALA are varied
and do not lend easily to clear cut recommendations , the potential benefits of
increased ALA and LCn3 intake outweigh the slight, if any, potentially negative
outcomes ( 1 37).

Cancer

At the present time, evidence supporting a beneficial role for n-3 fatty
acids in the prevention and treatment of a variety of cancers is much stronger in
animal models and cell cu lture studies tha n in human epidemiological studies
(95). Benefit of n-3 fatty acids has been reported with human breast (1 64 ),
colorectal (1 65-1 67), pancreatic (1 68, 1 69), lung (1 69-1 71 ), prostate (1 72-1 74),
and skin cancer (1 75, 1 76), however, the conclusions have not always been
consistent and the overall effect of n-3 fatty acids and cancer in humans remains
uncertain. Several plausible mechanisms for potential benefit have emerged
from cell and animal studies, with inhibition of AA derived eicosanoids
representing the most promising explanation of benefit (1 77, 1 78). AA derived
PGE2 prod uction has been implicated in several key pathways that promote
proliferation of cancer cells, growth of a capillary su pport system (angiogenesis),
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and metastasis of cancer cells to other tissues (179, 180). Other potential
mechanisms include: inhibition of tumor proliferation through the agonism of
PPARy, reduction of NFKB activation and TNFa expression, reduction in ras
oncogene induction, COX-2 supression, reduction in cytochrome p450
aromatase activity resulting in reduced estrogen production, and upregulation of
antioxidant enzyme systems contributing to the amelioration of reactive oxygen
species as potential pro- tumorigenic mutagens ( 178, 181).

One of the

potential reasons for contradictory findings between animals and humans may be
that the doses given in animal studies looking at the association between n-3
fatty acids and cancer exaggerate the likely effects in humans (178). This
problem emphasizes the motivation of the current study to determine "human
equivalent" n-3 fatty acid doses for animals that can offer better predictive value
to anticipated effects in human trials.
EPA intake has also been implicated as a treatment option for cancer
related cachexia (182). Though initial findings looked as though EPA may
improve appetite, weight status, and possibly even survival (183, 184); larger
comparative trials have not shown any significant improvements ( 1 85-1 87) with
administration of EPA.

Inflammation
Several disease states that have an underlying inflammatory component
may benefit from the potential anti-inflammatory action of n-3 fatty acids. These
include: cardiovascular disease (188), rheumatoid arthritis (189), air-way
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inflammation (asthma), systemic lupus erythematosis, and inflammatory bowel
disease (190). Eicosanoids derived from AA act as stimulants of inflammation
and systemic immune response through cyclooxygenase and lipoxygenase
products, particularly, PGE2 and LT84 (191). EPA competes as a substrate for
COX and LOX and the resultant 3-series prostaglandins and 5-series
leukotrienes are less inflammatory than the AA derived products. In addition to
modifying eicosanoid production, fish oil supplementation has been shown to
suppress the expression of IL-1� (192-195), TNF -a (194, 195), and IL-6 (194),
with ALA supplementation also decreasing IL·1� (195), TNF-a (195), and IL-6
expression (196). Habitual intake of EPA + DHA were also shown to be inversely
associated with the expression of plasma TNF receptors (8). Though the ability
of n-3 fatty acids to attenuate the inflammatory and immune response is
desirable in these disease states, it should also be noted that a reduction in
immune response elicited by n-3 intake may be an unwanted outcome in those
individuals fighting an infectious disease (197), and particularly those who are
already immunocompromised (ex: the elderly).

Diabetes
N-3 fatty acids do not appear to offer significant beneficial effects for the
treatment of diabetes mellitus. A recent report investigating the effect of n-3 fatty
acids on several cardiovascular disease risk factors concluded that n-3 fatty
acids had no significant effect on hemoglobin A 1 C levels, and had no consistent
effect on fasting blood sugar or fasting insulin levels (158). While impaired
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glycemic control has been reported in some studies with high supplemental n-3
doses (198, 199), n-3 fatty acids are generally found to have no significant
effects on glycemic control (200-206), including an18 study meta-analysis which
found no significant effects of n-3 fatty acid supplementation on fasting glucose
or hemoglobin A1C levels in Type 2 diabetics (207).

Psychological disorders
The high levels of DHA found in brain tissue coupled with the discovery
that n-3 fatty acid status in various tissues (mainly RBC PL) is decreased in
schizophrenia (208), adult (209) & childhood (210) attention-deficit/hyperactivity
disorder, and depression (211, 212), has stimulated research looking at possible
connections between n-3 fatty acid intake and several psychological disorders.
Supplementation has been found to improve objective measures of unipolar
depressive disorder (213), dark adaptation in dyslexia (2 14), and has been
reported to lengthen the remission of symptoms in patients with bi-polar
depression (215). In general, the majority of studies in schizophrenics have also
shown a beneficial effect from EPA supplementation (2 16) when compared to
placebo controls (2 17-2 19) with few exceptions (220). N-3 fatty acids have also
been suggested for attention-deficit I hyperactivity disorder and other childhood
developmental disorders, though two recent placebo-controlled trials
supplementing DHA did not report an improvement in ADHD symptoms (22 1,
222), with another study reporting no improvement in physical aggression in
children who were supplemented with EPA + DHA (223). An interesting
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hypothesis put forth by Hibbeln et al., suggests that mortality from coronary heart
disease and depression increases across several countries as n-3 fatty acid
intake declines (224, 225). This further potentiates the role of n-3 fatty acids in
psychological phenomena and this area of research calls for large scale definitive
trials for conclusive answers.

Pre and postnatal development
Increased understanding of the important role that n-3 fatty acids
(particularly DHA) play in brain and retina development has stimulated many
studies examining the effect of n-3 supplementation during different stages of
development, for example, the impact of maternal diet on prenatal development
and the mode of feeding (breast milk, standard formula, or formula with added
long chain PUFA) on postnatal development in term and pre-term infants. These
studies were recently reviewed by an expert committee workshop of the Child
Health Foundation (226) producing recommendations for maternal and infant n-3
intake based on available evidence of potential benefits. Thus far, it is generally
considered unnecessary for pregnant women to supplement n-3 fatty acids (226),
though it is encouraged that they include DHA rich foods in their diet. Attention to
n-3 fatty acid status may prove particularly beneficial in specific subgroups of
pregnant women, such as vegetarian women and women who are pregnant
subsequent to a first birth (based on the finding that DHA status is best in the first
child and maternal stores of DHA decline in subsequent pregnancies (59)). After
birth, it is highly encouraged that infants are breast fed (226). It is also
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encouraged that infants who are not breast fed receive formula supplemented
with AA and DHA (226, 227), with higher concentrations of AA and DHA for
preterm infants (226), based on a greater potential for benefit of supplementation
in preterm infants (53, 64, 228, 229).

Safety of fish consumption
Parallel to increasing public and scientific interest in n-3 fatty acid benefits,
regulatory agencies such as the Environmental Protection Agency and the FDA
have expressed concern touting the link between fish consumption and
methylmercury exposure. As a by-product of industrial emissions and
volcanoes, mercury finds it way into water bodies through environmental
precipitation (230). Predatory fish become the main repository of mercury
accumulation through successive concentration at each level of the food chain
(231). Nervous system tissue is the most vulnerable to mercury exposure,
particularly fetal neural tissue (232). Research findings have been contradictory
as to the impact of mercury from fish consumption on possible heart related
benefits. Guallar et al. (233), found an association between mercury level in
toenail clippings and risk of myocardial infarction incidence in men, while
Yoshizawa et al. (234), did not find an association between mercury levels and
incidence of coronary heart disease. Current advisories suggest that women
who are planning a pregnancy or are currently pregnant or lactating and young
children should avoid four types of fish with the highest mercury content: tilefish,
swordfish, king mackerel, and shark (235), while other demographic groups
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should balance fish intake between those with high and low mercury content
(Table 1 -4). It is likely that potential harm from mercury exposure based on
current fish consumption patterns is outweighed by the potential benefits,
particularly for those who are at risk of coronary heart disease (9, 230, 231). An
alternative source of n-3 fatty acids is refined fish oil supplements, which have
very low mercury content (231). More research is needed to fully understand the
potential risk of mercury exposure and possible counterproductive impact on
cardiovascular benefits provided by fish consumption.

1 .3

Animal model research and omega-3 fatty acid supplementation

Animal models in research
According to the National Research Council (236), an animal model is "a
living organism in which normative biology or behavior can be studied, or in
which a spontaneous or induced pathological process can be investigated, and in
which the phenomenon in one or more respects resembles the same
phenomenon in humans or other species of animal (as modified in (237))."
Several animal models are currently used in biological research, including: mice,
rats, hamsters, rabbits, guinea pigs, monkeys, dogs, and swine. Animal models
are not intended to perfectly mimic human function (238-240), but to provide a

35

Table 1 -4
FDA/ EPA recommendations for fish intake 1

Fish to avoid

Fish to consume in
limited quantities
(up to 6 ounces/wk.)

Fish to consume in
limited quantities
(up to 1 2 ounces/wk.)

Shark
Swordfish
King Mackerel
Tilefish
(a.k.a. Golden bass,
Golden snapper)

Canned Albacore
"White" Tuna

Canned Light Tuna
Sea Bass
Gulf Coast Oysters
Marlin
Halibut
Pike
Walleye
White Croaker
Largemouth Bass
Mahi Mahi
Blue Mussel
Cod
Eastern Oyster
Channel Catfish (wild )
Great Lakes Salmon
Gulf Coast Blue Crab
Lake Whitefish
Pollack

Fish lowest in methyl mercury:
Catfish (farmed), King Crab,
Flounder (summer), Scallops,
Trout (farmed), Salmon (wild
Pacific), Shrimp, Tilapia, Sardines

1

Recommendations are for women who are/ may become pregnant, are nursing, and small
children.
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"surrogate" (241 , 242) that is often better controlled and better able to answer
narrow research questions than could be determined from highly variable human
activity (243). Specimens from inbred animal strains (ex: mice) used in research
are almost genetically identical (244 ), thus eliminating much of the inherent
genetic variability found in human studies performed on mixed populations . The
choice of a particular animal model depends on the research question that is
being investigated and how closely a species matches humans in the mechanism
of inquiry (243). Selection of the appropriate animal model is also based on
criteria such as: availability of a particular model to many investigators , handling
ability of a particle animal, multiparous reproduction, adequate yield of
specimens necessary for assessment (245), and precedence of research using a
particu lar model in the field of study (246). In addition, proliferation of genomic
research in recent years has increased the selection of models based on known
genetic homology between humans and animals (243).

Advantages of the murine model

There are several advantages to using the mouse model in nutrition
research . Mice are generally inexpensive to purchase and feed (though cost
depends on genetic strain and diet selection). Small size allows for caging of
multiple animals in groups and requires less space than other models (24 7).
Mice reproduce quickly (247) and are multiparous (246), which has contributed to
the formation of several inbred strains for purchase , which are nearly 1 00%
homozygous (246). The wide use of rodents over the last century has produced
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a plethora of publication precedence, making the mouse model more trusted than
newer, less documented models. In recent years, both the mouse (248) and
human genome (249) have been categorized, revealing a relative 70-90%
genetic homology between mice and humans (250). This has made mice a
particularly useful model for studying human biological processes that have been
conserved between the two species (244, 251 ). Specifically, mice are useful for
n-3 fatty acid research because the same fatty acids are essential in mice and
humans. Mice also metabolize fats through the same pathway and house the
same enzymatic machinery for polyunsaturated fat processing as humans (66).

Disadvantages of the murine model
Few disadvantages exist in the use of the mouse for nutrition research. In
reference to their use in lipid metabolism, it has been reported that �5 and �6
desaturase activity in rodents is greater than the rate of human desaturases
(252 , 253). This detail is sometimes cited in an attempt to discredit the use of the
mouse model as a surrogate for human fatty acid metabolism. However,
expectation and quantification of this rate difference should not hinder
reasonable extrapolation to humans from murine data. It has also been shown
that DHA levels in several human tissues are reduced compared to rodents
(254), further suggesting a possible difference in conversion capacity.

Another

possible disadvantage is that mice are not considered a high fidelity model for
certain human diseases such as the development of atherosclerosis. This is due
to the difference in predominant cholesterol carrying lipoproteins between
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rodents and humans (255). This is also based on the resistance of rodents to
dietary fat induced atherosclerosis (255).

Design improvements for murine model research with omega-3 fatty acids

Choice of control/background diet
We have observed that one of the significant methodological problems
with rodent studies supplementing n-3 fatty acids is the use of a control
(background) diet that is not representative of typical human consumption
patterns. When supplemented groups are compared to control diets that are
devoid of long chain polyunsaturated fatty acids EPA, DHA, and AA, the results
will likely demonstrate exaggerated increases of n-3 fatty acids in a variety of
tissues due to the lack of metabolic constraints enforced by the presence of other
LCn3 and AA in the control diet. We believe the solution to this problem (as
detailed below and in Chapters 2 and 3) involves the calculated addition of all
polyunsaturated fatty acids in a manner that is representative of their relative
proportion in the typical (Western) human diet. It has been suggested that, " . . . if
the (experimental) design inadequately represents the 'normal' life conditions of
the target species, inaccurate conclusions may be drawn, regardless of the value
of the model itself' (240). When applied to nutrition studies, this statement
highlights _the need for the diet design of the model species (in this case, mice) to
model the diet of the target species (humans) in order for accurate conclusions to
be drawn from the analysis.
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Relevant dosing
A recent survey of general studies using supplemental n-3 fatty acids in
rodents shows that current supplemental doses are not representative of
reasonable expected human consumption (Table 1-5). Standardization of
supplemental n-3 fatty acid doses in mice that represent a "human equivalent
dose" is necessary if animal studies are to have true predictive value for humans.
The precedent for change, in part, comes from observations in toxicological
studies utilizing, "physiologically based pharmacokinetic" (PBPK) modeling (256)
(also called "biologically based dose-response (BBDR) (257, 258)).
Physiologically based modeling is meant to reduce extrapolation of dosages
between two species to a mathematical model (257) that is based on the
metabolism of the given substance in each species. Building on this concept, it is
feasible that a mathematical model describing the expected influence of dietary
n-3 fatty acids on the same endpoints in different species can be derived. Below,
we introduce a simple mathematical model for the standardization of
supplementation that allows for direct comparison of biological endpoints
between rodents and humans. We have put forth a rudimentary, easy to use,
estimation of this model with the knowledge that a more precise estimation in the
future may be necessary.
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TABLE 1-5
Review of supplemental doses of omega-3 fatty acids
given in recent rodent studies.

Study

ALA

EPA

HED 1

DHA

grams

----- energy % ------ALA
Cognault et al. (259)
Massiera et al. (260)
Miyazawa et al. (261)
Mori et al. (262)
Morise et al. (263)
Takemura et al.(264)
Saito et al. (265)
Oarada et al.(266)
Ide, et al.(111)
Kim et al.(267)
Takahashi et al. (268)
Maison et al.(269)
Choi-Kwon et al. (270)
Joshi et al. (271)
Akisu et al. (272)
Oarada et al. (273)
Watanabe et al. (274)
Wang et al. (275)
Cha et al. (276)
1

16.8
5.7
3.6
23.2
13.8
11.4
8.2
16.1
16.7
10.6
23.9

7.8
5.1
2.9
1.2
3.8
6.9
10.2
3.5
2.4
3.4
5.4
5.4

7.6
3.3
8.6
6.2
12.4
4.0
7.5
2.3
1.7
2.3
5.4
5.4
9.7
2.6
6.5

37.3
12.7
8
51.6
30.7
25.3
18.2
35.8
37.1
23.5
53.1

Human Equivalent Dose based on energy% of a 2000 calorie diet.

EPA

DHA

17.3
11.3
6.4
2.7
8.4
15.3
22.7
7.8
5.3
7.6
12
12

16.9
7.3
19.1
13.8
27.6
8.9
16.7
5.1
3.7
5.1
12
12
21.6
5.8
14.4
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Significance of omega-3 fatty acid form
The media as well as medical professionals often propagate a blurred
distinction between the expected attributes of ALA and those of LCn3, EPA, and
DHA. N-3 fatty acids are lumped together as a unified entity and even prescribed
almost interchangeably. The benefits reviewed above show that there is a much
greater research base supporting a beneficial effect of LCn3 intake than for ALA.
We have attempted to further clarify this difference in the context of an
experimental design with background long chain fatty acids and supplemental
doses that better represent human intake. This comparison is necessary to
demonstrate the individual effects of ALA and LCn3 on tissue accumulation,
conversion to metabolites, and influence on pertinent endpoints.

1.4

Summary
Jon R. Held summarizes the purpose of animal model research as follows,

"The whole history of biomedical research tells us the countless benefits to
humans obtainable by asking the right questions of the right animal model (237)."
We believe that the validity of n-3 fatty acid research in the rodent model extends
only as far as the design of the experiment. Supplemental studies in animals are
by nature wrought with many complex associations between the diet of man and
the murine diet. In order for the "right question" and the "right animal model" to
yield meaningful answers, methodological changes are necessary in the way that
n-3 fatty acid research in rodents is performed.
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1.5

Research Objecti\fe

1. To develop a hypothetical diet model for the study of n-3 fatty acids in rodents
that allows for better comparison of mouse and human endpoints.
2. To clarify the relative impact of n-3 fatty acid form and amount on measurable
biological endpoints.

Specific aims
1. To test the use of energy% as a model for the addition of fatty acids
to rodent diets with comparison to archival human data.
2. To compare the effect of ALA and EPA on plasma and erythrocyte
phospholipid fatty acid content when these fatty acids are given at
equivalent
supplemental levels in the context of a background diet
'
that contains long chain PUFA (n-3 and n-6).
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2

RELEVA1N T DOSING FOR ANIMAL MODELS: A SCALING APPROACH

2.1

Introduction
The design and implementation of dietary research with animal models

requires thoughtful examination of interspecies variation. In order for data
achieved from these studies to be used for meaningful extrapolation, levels of
supplemental nutrients must be a reasonable representation of what can be
consumed by humans. Are we considering these interspecies differences when
we design dietary studies, or has the use of animal models become so
widespread that we have overlooked the need for calculated extrapolation? If
dietary animal studies are to have true predictive value for anticipated results in
humans, we must stretch beyond the scope of nutrition and adopt an integrative
perception of animal modeling that considers the discoveries of parallel
disciplines.
A natural starting point for this integration is the study of basal metabolic
rate and its relationship to bodyweight in mammals. The analysis of metabolic
rate has been one of the most prevalent examples of interspecies comparison
over the last century. In 1932, Max Kleiber, well known pioneer in the field of
animal energetics, discovered that over a large range of animal size (from rats to
oxen) linear regression of the logs of weight and metabolic rate produced a ¾
exponent (277-279) based on the following equation:
Y= axb
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Where Y is metabolic rate in kcal, x is bodyweight in kilograms, a is the
proportionality constant, and b is the scaling exponent and the slope of the
regression line depictiing this relationship (280). Kleiber's discovery differed from
a long held reliance on ½, which was the anticipated exponent from geometric
evaluation of surface area and volume alone (281, 282). Shortly after Kleiber's
discovery, Brody et al. (283), added more mammals to Kleiber's analysis and
deduced the same scalin�i exponent, ¾ , for animals ranging in size from a
mouse to an elephant, yielding the often cited "mouse to elephant curve".
However, ¾ scaling was not without its dissenters. For a variety of reasons,
several researchers have held firm to ½ scaling (284-288).
In the past decade, there have been many interesting attempts to expand
our understanding of why Kleiber's ¾ scaling may exist in nature. West et al.
(289-293), have presented several papers detailing the physical constraints of
"hierarchical branching networks" within organisms that dictate a ¼ (or multiple
thereof, including ¾ ) scaling between many biological variables and bodyweight.
This theory was tested in mammalian species, birds, plants, unicellular
organisms, sub-cellular fractions (mitochondria), and enzymes; and the
conclusion was made that metabolism is confined to the dimensions of circulation
and circulation is dictated by the same fractal geometric confines from one
species to another. Other views supporting ¾ scaling include:
•

A "multiple cause model of allometry"(294) that takes into account every
ATP utilizing and generating construct within the biological system that
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contributes to metabolic rate ( Ex: organ size, hormonal state,
temperature, pressure, ecological parameters, etc.. . ) (295-297)
• An ecological perspective (298), in which the relationship between
metabolic rate and body size is examined based on the influence of
geographical region of evolution.
•

The use of geographical food productivity and abundance (299) to
determine the influence of food availability in different regions on
metabolic rate.

Figure 2-1 summarizes some of the major theories used to explain the scaling of
metabolic rate between animal species and how this fits into the scheme of
dietary intake.
Three-quarter power scaling in nature is an example of how comparative
physiology can be used to guide the design of animal model research, and
particularly, the dosing of supplemental components in dietary studies using
animal models. Currently, no clear standard of practice drives the derivation of
nutrient doses in dietary animal model research. Doses are conceived based on
various methods such as: comparison of weights between animals and humans,
duplication of doses from similar studies, and in some cases, dosing values
derived merely to maximize the potential for positive results without conscious
interspecies evaluation. Therefore, we set out to establish a mathematical model
that could be used as a guideline for choosing levels of n-3 PUFA in rodent diets
that would facilitate reasonable extrapolation to humans. In order to be useful,
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Figure 2-1: I nterconnection of metabolic rate scaling theories and effect on nutrient requirement and intake.
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this model should: linearize the relationship between human and rodent data; be
applicable to the general range of n-3 fatty acid studies; be tested on the basis of
its ability to yield similar biological effects in animal models and humans; and
most importantly, be simple to use.
Because supplemental components in dietary studies either have caloric
value or are dependent on the difference in metabolic rate between species, we
suggest that a model based on consideration of daily energy consumption in
rodents and humans may offer a means of dose standardization. The
comparison of daily energy consumption between two organisms (ex: between
mouse and man) should be an indirect picture of the differences in digestion,
absorption, energy expended in activity, metabolic rate, and nutrient needs
between the two organisms, particularly if they are in energy balance with no net
weight gain or loss. Supplementation based on energy consumption is
supported by Rucker et al., who suggest, ". . . when making interspecies
comparisons from a nutrition perspective, the strongest case is made when a
measure of metabolic body size or food intake, rather than bodyweight is used to
extrapolate the dosages required for a given response" (300). Rucker also
points to the inherent similarity between caloric needs and water-soluble vitamin
requirements in homeotherms (301 ). Since vitamin requirements and caloric
intake are under similar biological controls, a "human equivalent dose" model
should be able to predict both the supplementation levels in animals that would
match human intake and should also be able to predict human vitamin
requirements from known animal vitamin requirements. Vitamin and mineral
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intake recommendations have been made for both rodents and humans, and
loosely represent perceived requirements. These known recommendations offer
a means to test the predictability of scaling theories between rodents and
humans.

2.2

Methods
Several published works have established the nutrient needs of humans

(302-306) and mice (307, 308). We used this information as a means to test the
ability of the following hypothetical models to predict the Dietary Reference
Intakes for humans from mouse requirements when used as a mathematical
conversion factor:
A. Bodyweight (in kilograms)
B. [Bodyweight (Kg)]" ¾
C. Daily energy consumption (% energy).
Derivation of the above scaling factors for mouse to human comparison is
detailed in Table 2-1. Briefly, human weight (Kg), [weight (Kg)] " ¾, and daily
calorie intake was divided by the same data for an average mature mouse to
produce a conversion factor based on each hypothetical scaling model (A-C).
Established murine vitamin and mineral intake recommendations were multiplied ·
by each conversion factor and compared to the Dietary Reference Intakes of
each nutrient for humans. The levels of linoleic acid (LA) and a-linolenic (ALA)
acid present in the typical daily intake of rodent diet were also used to test the
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TABLE 2-1

Derivation of conversion factors

Bodyweight (Kg)
[Bodyweight (Kg)]A ¾
Daily caloric intake

Mouse1

Human

Human
Mouse

0.025
0.063
1 4.4

70
24.2
2000

2800
384.8
1 38.89

1 Based on a C57BU6J adult mouse, consuming 4gms/day AIN93M diet (307
).

predictive value of each factor to estimate human adequate intake (Al) of LA and
ALA.

2.3

Results
Table 2-2 details the use of each conversion factor to estimate the Dietary

Reference Intakes for vitamins, minerals, and fatty acids (LA and ALA) from
known mouse nutrient requirements (307). In comparison to the factors based on
weight (Kg) and [weight (Kg)] ¾, the factor for energy% best predicted the DRls
for 1 2 of 1 2 vitamins and 9 of 1 2 minerals. The minerals in which energy% was
not the best scaling predictor were sodium, potassium, and chloride. The
estimations based on energy% were also the best predictor for the Al of LA and
ALA in humans.

01
0

TABLE 2-2
Scaling of daily nutrient requirements for mice to human Dietary Reference Intakes

1• 2

Scaling Factors

Nutrient

Daily Requirement

Body Weight (Kg)3

75 3
[Body weight (Kg)]A·

°lo Energy4

RDA/Al5

0.02 1 4
0.024
0.0233
0. 1 2
8
0.8
0.201
3
4.8
3
0. 1
0.0586

59.9
67.2
65.2
336
22,400
2240
563
8400
1 3440
8400
280
164

8.2
9.2
9.0
46
3079
308
77
1 1 55
1 847
1 1 55
38
23

3.0
3.3
3.2
17
1111
111
28
417
667
417
14
8

1 .2
1 .3
1 .3
16
400
30
15
5
900
1 20
2.4
5

1 9.99
7.98
14.40
4.1 1
6.29
2.026
8
24.2
0.83
0. 1 4
0.6
0. 1 2

55972
22344
40310
1 1 505
17614
5673
22,400
67, 620
2,325
392
1 ,680
337

7695
3072
5542
1 582
2421
780
3079
9,296
320
54
231
46

2776
1 1 08
2000
571
874
281
1111
3,354
1 15
19
83
17

1 000
700
4700
1 500
2300
400
35
900
1 50
8
55
11

VITAMINS
Thiamin
Riboflavin
Vitamin 86
Niacin
Folate
Biotin
Vitamin E
Vitamin D
Vitamin A
Vitamin K
Vitamin 8 1 2
Pantothenate

mg
mg
mg
mg
µg
µ9
6
mg
µg
7

J.!9

µg
µg
mg

MINERALS
Calcium
Phosphorus
Potassium
Sodium
Chloride
Magnesium
Chromium
Copper
Iodine
Iron
Selenium
Zinc

mg
mg
mg
mg
mg
mg
µg
µg
µg
mg
µg
mg

TABLE 2-2

Continued
Scaling Factors

Nutrient

Daily Requirement

Body Weight (Kg)3

75
[Body weight (Kg)JA·

0.01 1
0.086

30.8
242

4.2
33

3

% Energy"

RDA/Al

1 .6
12

1 .6
15

5

FATTY ACIDS
a-linolenic acid
Linoleic acid

2

g m (302)
gm (302)

Soutte: 4*02-309, 308) •

Based on 4 grams (average daily intake) of AI N93M purified rodent diet.
Based on a 70 Kg human and 25 gram mouse.
• Based on 14.4 calories (average daily mouse intake based on 4 grams AIN93M diet) (307) and 2000 calorie human diet.
5
Based on 30 year old male
6
a-tocopherol
7
µg retinol
3

01

.....a..
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2.4

Discussion
Selection of appropriate doses for supplemented nutrients in animal

studies is a common challenge faced by nutrition researchers. Extrapolation of
animal model data to humans necessitates the use of supplemental doses that
are both biologically relevant and reasonable for human intake. However, there
are currently no standards of practice guiding researchers in the addition of
dietary components in animal studies other than precedent. In the words of
Yates, et al., "We need principles of data extrapolation to justify transforming

data from one system (species) into data about another, different system. We
need to know what scaling principles can guide the designs of our experimental
protocols" (309). The tentative search for a "human equivalent dose" lies at a
complex intersection of diverse fields of insight, from comparative physiology and
evolutionary biology, to bioenergetics and theoretical mathematics. It is from this
intersection, with consideration and input from this diversity, that we present a
simplified approach to relevant nutrient dosing in animal studies.
Dietary recommendations for animals are formulated to meet daily dietary
requirements and to avoid un-utilized excesses. Diets are formulated to provide
levels of nutrients to support growth, reproduction, lactation and maintain health.
As such, micronutrient and amino acid compositions of these diets are well
characterized and defined. Any deviation from recommended nutrient levels
requires appropriate justification. This is not the ca�e with dietary fats. While the
lipid content has been standardized in rodent diets to provide either corn oil at
5% (w/w) (eg., AI N76A) (239) or soybean oil at 4% or 7% (w/w) (AI N93M or
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AIN93G, respectively) (307), liberties are taken with fatty acid compositions that
appear to lack reasonable justification; such as replacing all the corn oil in a diet
with pure coconut oil to simulate a high saturated fat diet. This is particularly true
with studies evaluating the dietary effects of n-3 PUFA. For example, a random
search of recent literature reveals the large variation of levels of n-3 PUFA that
are provided in rodent diets, primarily at the expense of corn oil. These intakes,
in the form of ALA, EPA and/or DHA, ranged from 2.6-40 energy% (Table 1-5).
This is in comparison with typical human intakes of 0.5 and <0.09 energy% for
ALA and EPA+DHA, respectively (6-8). Will these levels produce biologically
relevant data if they are incompatible with human consumption? While the uses
of PUFA are tailored for the objectives of each study, it seems reasonable that
guidelines framing appropriate levels are needed, with justification warranted
when unusual deviations from these guidelines occur.
Recently, Rucker and Storm (300) discussed approaches that have been
used to extrapolate nutrient intakes to that of humans. Their paper plotted the
log 1 0 of body weight (Kg) against the 10910 of nutrient intake (mg) in 5 different
species, including humans. In doing so, metabolic differences of species were
taken into account and the relationship of nutrient intake versus body weight for
each of the species became linear. Similarly, we are interested in establishing a
mathematical model that provides the foundation for allometric scaling of dietary
PUFA intake between rodent and humans.
Evaluation of several different conversion factors lends credence to a
dosing model based on energy% as an appropriate factor for dietary components
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between species. Though energy % is not a precise match for every nutrient,
overall, it produces a better match to human nutrient recommendations than
factors based on bodyweight (Kg) or [bodyweight] A ¾. Precise mathematical
modeling of the relationship between an animal's nutrient needs and the DRls is
beyond the scope of this paper, however, we believe that allometric scaling
based on an energy % factor produces a better model for derivation of a "human
equivalent dose" than other methods currently employed. In order to further test
the predictive value of em�rgyo/o dosing in mice and humans, we have also tested
this hypothesis in the form of a pharmacodynamic experiment with omega-3 fatty
acid supplementation and hematological endpoints in both species (Chapter 3).

2.5

Conclusions
We suggest that adding dietary components on the basis of energy % is

an efficient way to narrow the gap between human intake and rodent intake. It is
our hope that the presentation of this model will stimulate necessary thought and
debate concerning the supplemental levels that are currently used in dietary
studies. Ideally, dietary studies of the future will represent a true integration of
theoretical comparative physiology and nutrition science. The issues raised here
are only the beginning.
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3

HUMAN EQUIVALENT DOSE MODELING FOR OMEGA-3 FATTY ACID
SUPPLEMENTATION IN C57BU6J MICE

3.1

Abstract
The rodent model is often used to study the impact of dietary n-3 fatty

acids on a variety of biological endpoints, and the results of these studies have
been used to explain anticipated effects of n-3 fatty acid intake in humans.
However, supplemental levels of n-3 fatty acids that are commonly used in
rodent studies do not represent reasonable human intake, by comparison.
Currently there is no standard method for the addition of n-3 fatty acids to rodent
diets. We tested a mathematical model for dosing supplemental levels of a
linolenic acid (ALA) and eicosapentaenoic acid (EPA) to rodent diets on the basis
of energy%. C57BI/6J mice were fed a background diet that modeled typical
Western intake in both macronutrient and fatty acid composition. Three levels of
ALA and EPA (0.3, 0.8, and 1.4 energy%) were supplemented to either a normal
ALA control diet (0.6 energy% ALA) or a high-ALA control diet (1.2 energy%
ALA). Plasma and erythrocyte phospholipid fatty acid changes were determined
and compared to archival human n-3 fatty acid supplementation studies reporting
the same tissue endpoints. In mice, supplemental EPA had a greater effect than
supplemental ALA on both plasma and erythrocyte phospholipid EPA.
Docosahexaenoic acid (DHA) levels in mice were only minimally changed by
either ALA or EPA supplementation. Use of the high- ALA control diet resulted in
attenuated phospholipid fatty acid changes in both tissues compared to the
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normal-ALA control diet for both supplemented fatty acids. At each
supplemented dose of ALA or EPA, changes in murine plasma or erythrocyte
phospholipid EPA exceeded changes observed in the same human tissues by
2-4 fold when compared to equivalent human supplemental doses in energy%.
Tissue changes observed using the high-ALA control diet better modeled the
results observed in humans at the same supplemental energy% for both ALA and
EPA in plasma and erythrocyte phospholipids. This is the first study to use
pharmacodynamic modeling to compare the effect of supplemental n-3 doses on
mouse and human endpoints. The addition of n-3 fatty acids to rodent diets on
the basis of energy% represents a reasonable improvement to current dosing
strategies. This data is useful, both as a guideline for n-3 fatty acid dosing in
rodent studies and as a reference point for future calculated refinements in
dosing.

3.2

Introduction
Recently, we suggested the use of energy% as a model for lipid dosing in

dietary research using the rodent model. Comparison of rodent nutrient
requirements and human intake recommendations reveal that an energy% factor
has better predictive value for estimating human requirements from animal
requirements than either weight (Kg) or (weight (Kg))¾ (Chapter 2). The current
study is designed to further test the applicability of an energy% model based on
the comparison of common biological endpoints in mice and humans. Energy%
is used as a tool to formulate a "Western" background diet as well as
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supplemental doses of two common n-3 fatty acids: a-linolenic acid (18:3n-3,
ALA) and eicosapentaenoic acid (20:5n-3, EPA). By capturing corresponding
mouse and human endpoints and standardizing the supplementation values on
the basis of energy%, we offer a touchstone for anticipated effects at these
doses and a template for further investigation in the quest for a "human
equivalent dose".

3.3

Materials and Methods

Animals
Male, C57BU6J mice (The Jackson Laboratory, Bar Harbor, ME) were
used in the following experiments. All mice were received at 35-42 days of age
and housed 5 per cage. Animals were given free access to food and water and
were maintained in a climate controlled facility with programmed light and dark
cycle. Mice were checked daily for health and general well-being. An Animal
Use Protocol was filed and approved by the University of Tennessee Institutional
Animal Care and Use Committee (IACUC).

Diets
All diets were prepared by Research Diets (New Brunswick, NJ) (Tables
3-1 and 3-2). The fatty acid ethyl esters were purchased from Nu-Chek Prep
(Elysian, MN). Aliquots of diet were bagged separately and stored at -20° C
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TABLE 3-1
Diet Composition - High ALA study
Diet Component

Control

ALA-1

ALA-2

ALA-3

EPA-3

EPA-2

EPA-1

---------------- g/kg ----------------Casein
L-Cystine
Cornstarch
Maltodextrin 1 0
Sucrose
Cellulose
Cocoa Butter
Linseed Oil
Palm Oil
Safflower Oil
Sunflower, Trisun1
1 8:3 n-3 ethyl ester2
-20:4 n-6 ethyl ester2 •
20:5 n-3 ethyl ester2
22:6 n-3 ethyl ester2
Mineral Mix S1 00263
Dicalcium Phosphate
Calcium Carbonate
Potassium Citrate
Vitamin Mix V1 3401 4
Chotine Bitartrate
a -Vitamin E Acetate5
Tertiary-butyl hydroquinone

230
3.4
266
86
115
57
43
5.2
60
33
31
3. 1 8
0.40
0. 1 7
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0.15
0.03

230
3.4
264

86
115
57
43
5.2
60
33
31
4.72
0.40
0. 1 7
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0.15
0.03

mi

231
3.4
259
86
1 15
57
43
5.2
60
33
31
7. 1 6
0.40
0. 1 7
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0.15
0.03

232
3.4
253
86
115
57
43
5.2
60
33
31
1 0.43
0.40
0. 1 7
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0. 1 5
0.03

232
3.4
253
86
1 15
57
43
5.2
60
33
31
3.21
0.40
7. 1 8
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0.15
0.03

231
3.4
259
86
1 15
57
43
5.2
60
33
31
3.20
0.40
4.25
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0.15
0.03

230
34
264
86
1 15
57
43
5.2
60
33
31
3. 1 9
0.40
1 .72
0.29
1 1 .5
15
6.3
19
1 1 .5
2.3
0. 1 5
0.03

:.

,
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High-Oleic acid sunflower oil, Humko Oil Products (Humboldt,
1 8:3 n-3, 20:4 n-6, 20:5 n-3, and 22:6 n-3 ethyl esters supplied by Nu-Chek Prep (Elysian, MN).
Components per Kg Mineral Mix: NaCl, 259 g; magnesium oxide, 41 .9 g, MgSO4 • 7 H2O, 257.6 g ; chromium potassium sulfate ·12 H2O, 1 .925 g; cupric carbonate, 1 .05 g ; sodium
fluoride, 0.2 g; potassium iodate, 0.035 g; ferric citrate, 2 1 .0 g; manganous carbonate, 12.25 g; ammonium molybdate, 0.3 g; sodium selenite, 0.035 g; zinc carbonate, 5.6 g; sucrose,
399. 1 05 g (Research Diets, New Brunswick, NJ).
4
Components per Kg Vitamin Mix: vitamin A palmitate (500,000 IU/gm), 0.8 g; cholecalciferol (1 00,000 IU/gm), 1 .0 g; menadione sodium bisulfite, 0.08 g; biotin (1 .0%), 2.0 g;
cyanocobalamin (0. 1 %), 1 .0 g; folic acid, 0.2 g; nicotinic acid, 3.0 g; calcium pantothenate, 1 .6 g; pyridoxine- HCI, 0. 7 g; riboflavin, 0.6 g; thiamin HCI, 0.6 g; sucrose, 988.42 g
{Research Diets, New Brunswick, NJ).
500 IU/gm
1

2

3

TABLE 3-2
Diet Composition-Normal ALA study

"

Diet Component

Control

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

1 70
3
336
85
1 14
57
40
5
56
31
29
7.5
5.2
0
0.4
1 .6
0.27
11
15
6
19

1 70
3
336
85
1 14
57
40
5
56
31
29
7.5
3.3
0
0.4
3.5
0.27
11
15
6
19

1 70
3
336
85
1 14
57
40
5
56
31
29
7.5
0
0
0.4
6.8
0.27
11
15
6
19

g/kg

Casein
L-Cystine
Cornstarch
Maltodextrin 1 0
Sucrose
Cellulose
Cocoa Butter
Linseed Oil
Palm Oil
Safflower Oil
Sunflower, Trisun 1
Total ethyl esters2
1 8: 1 n-9 ethyl ester
1 8:3 n-3 ethyl ester
20:4 n-6 ethyl ester
20:5 n-3 ethyl ester
22:6 n-3 ethyl ester
Mineral Mix S1 00263
Dicalcium Phosphate
Calcium Carbonate
Potassium Citrate

1 70
3
336
85
1 14
57
40
5
56
31
29
7.5
6.7
0
0.4
0. 1 7
0.27
11
15
6
19

1 70
3
336
85
1 14
57
40
5
56
31
29
7.4
5.2
1 .4
0.4
0. 1 7
0.27
11
15
6
19

1 70
3
336
85
1 14
57
40
5
56
31
29
7.4
3.3
3.3
0.4
0. 1 7
0.27
11
15
6
19

1 70
3
336
85
1 14
57
40
5
56
31
29
7.4
0
6.6
0.4
0. 1 7
0.27
11
15
6
19

01
(0

0)
0

TABLE 3-2
Continued

Control

Diet Component

4

Vitamin Mix V1 3401
Choline Bitartrate
a -Vitamin E Acetate5
Tertiary-butyl hydroquinone

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

---------------- g/kg ----------------11
2
0.1 5
0.03

11

2
0.15
0.03

11
2
0.15
0.03

11
2
0. 1 5
0.03

11
2
0. 1 5
0.03

11
2
0. 1 5
0.03

11
2
0. 1 5
0.03

1
High-Oleic acid sunflower oil, Humko Oil Products (Humboldt, TN).
z All ethyl esters supplied by Nu-Chek Prep (Elysian, MN).
3
Components per Kg Mineral Mix: NaCl, 259 g; magnesium oxide, 41 .9 g, MgS04 • 7 H20, 257.6 g; chromium potassium sulfate · 1 2 H20, 1 .925 g; cupric carbonate, 1 .05 g; sodium
fluoride, 0.2 g; potassium iodate, 0.035 g; ferric citrate, 21 .0 g; manganous carbonate, 1 2.25 g; ammonium molybdate, 0.3 g; sodium selenite, 0.035 g; zinc carbonate, 5.6 g; sucrose,
399. 1 05 g. (Research Diets, New Brunswick, NJ).
4
Components per Kg Vitamin Mix: vitamin A palmitate (500,000 IU/gm) , 0.8 g; cholecalciferol (1 00,000 IU/gm), 1 .0 g; menadione sodium bisulfrte, 0.08 g; biotin (1 .0%), 2.0 g;
cyanocobalamin (0. 1 % ), 1 .0 g; folic acid, 0.2 g; nicotinic acid, 3.0 g; calcium pantothenate, 1 .6 g; pyridoxine- HCI, 0. 7 g; riboflavin, 0.6 g; thiamin HCI, 0.6 g; sucrose, 988.42 g.
{Research Diets, New Brunswick, NJ).
500 IU/gm
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under an atmosphere of nitrogen to minimize fatty acid oxidation. Animals were
provided fresh diet each day.

Background diet
This research employed two diets as the background diet, the US 17 diet
(310) (Research Diets, New Brunswick, NJ; diet # D12486B) and a modified
version of the US 17 diet (Research Diets, New Brunswick, NJ; diet #
D050 1080 1). The US 17 diet was originally designed to mimic the Western diet
with regards to lipid and fatty acid composition (saturated, monounsaturated, and
polyunsaturated fatty acids). The PUFA content was limited to linoleic acid (LA)
and a-linolenic acid (ALA) to allow for the addition and evaluation of other dietary
PUFA (310). One of the experiments used the US 17 diet as the background diet
(High ALA, H-ALA); however, for the other study (Normal ALA, N-ALA) the
macronutrient distribution was revisited and these values were adjusted to better
reflect the protein and carbohydrate content of the Western diet (based on %
kilocalories) (Table 3-3) (311) . The protein content was adjusted from 21
energy% (original US17 formulation) to 16 energy%, and the carbohydrate
content was changed from 43.2 energy% to 50 energy%. The background lipid
content was retained at -34 energy%. While we had no intention of modifying
the protein and carbohydrate content of the background diet between the studies,
it was brought to our attention that the protein content of the original US17 diet
was high following the first experiment. Although we have no data to suggest

a>
I\.)

TABLE 3-3
Comparison of High ALA and Normal ALA control diets with typical Western consumption
Diet Component

High-ALA Diet

Normal-ALA Diet

43.2
21
35.8
14.3
1 2.9
8.6

Fatty Acids:
1 8:2 n-6
1 8:3 n-3 (ALA)
20:4 n-6 (AA)
20:5 n-3 (EPA)
22:6 n-3 (DHA)

7.4
1 .2
0.08
0.034
0.058

1

2

2

HED
N-ALA

Typical Intake

-------- gms

energy %
Carbohydrate
Protei n
Fat:
MUFA
SFA
PUFA

HED 1
H-ALA

50.0 - 52.6 en % (31 1 )
1 4.6 - 14.9 en % (31 1 )
32. 1 - 32.3 en % (31 1 )
1 4 en % (89, 3 1 2)
1 1 en % (31 1 )
7 en % (89, 3 1 2)

50
16
34
15
1 1 .6
7.4
6.92
0.6
0.08
0.034
0.054

1 6.4
2.6
0. 1 77
0.075
0. 1 28

Human Equivalent Dose based on energy % equivalent in a 2000 calorie diet.
Source:(31 4)and personal communication: Angela Gajda, Research Diets, New Brunswick, N .J.

1 5.3
1 .3
0. 1 77
0.075
0. 1 20

1 3-1 7 gms (89, 3 1 2)
1 . 1 -1 .8 gms (6, 7, 3 1 2)
- 1 70 mg (89, 3 1 3)
1 00-200 mg,
EPA + DHA (6, 7)
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otherwise, a search of the literature did not reveal any evidence that the tissue
phospholipid fatty acid composition would be significantly affected by these
changes. Nevertheless, this should be considered when evaluating the results.
Because the typical Western diet contains small amounts of arachidonic
acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (in
addition to LA and ALA), each of these fatty acids (AA, EPA, and DHA) was
added to all diets at a dose that modeled typical Western consumption (based
on caloric density) (Table 3-3) (6, 7, 313, 315).

Control diets

Two dietary studies (Normal ALA and High ALA) were designed to test
the effects of increasing supplemental amounts of dietary ALA or EPA on
v changes in plasma and erythrocyte phospholipid PUFA content. The Normal
ALA (N- ALA) study employed a control diet containing ALA at a level of 0.6% of
energy, whereas the High ALA (H-ALA) study used a control diet containing
ALA at a level of 1. 2% of energy (Table 3-3). These levels are equivalent to
1.3 g/d and 2.6 g/d when extrapolated based on caloric density (2000 kcal/d).
According to the DRls, the Al for ALA is 1.1 g/d for women and 1.6 g/d for men
(302); which is equivalent to 0.5% -0.7% energy. The LA content of the diets
was designed to be kept constant at-7% of energy.
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Experimental diets
Experimental diets for both studies were formulated using the control diet

as a base for supplemented fatty acids. Ethyl esters of ALA or EPA at levels of
approximately 0.15%, 0.4%, and 0.7% (w/w), which is equivalent to 0.3%, 0.8%,
and 1.4 energy%, respectively, were added to both control diets (Table 3-4).
Supplemental doses were low enough that changes in total fat content between
. treatment groups would not be expected to confound results attributed to
supplemental fatty acids. However, in the Normal-ALA study, fatty acids were
supplemented such that any changes in tissue PUFA phospholipid content could
only be attributed to the supplemented n-3 PUFA, by adding supplemented ethyl
esters at the expense of neutral fatty acid oleic acid (18:1 n-9).

The upper

supplemented dose represented by groups ALA-3 and EPA-3 is equivalent to the
maximum levels of long chain n-3 PUFA recommended by the U.S. Food and
Drug Administration (3 g/d) (11) (Table 3-4). The fatty acid compositions of the
experimental diets in the Normal-ALA study and the High-ALA study are
presented in Tables 3-5 and 3-6.

Experimental design
For both studies, mice were randomized into respective diet groups upon
arrival, by weight. Mice were fed a standard pre-experimental powdered diet mix
for acclimatization to powdered meals. Mice were then fed treatment diets for
20-21 days ad libitum. At the end of the diet treatment period mice were fasted

TABLE 3-4
Treatment groups and supplemental doses in High and Normal ALA studies

High-ALA

-

Supplemental
ALA or EPA

Supplemental
ALA or EPA

HED

wt %

energy %

ALA-1
ALA-2
ALA-3

0.1 5
0.40
0.73

EPA-1
EPA-2
EPA-3

0. 1 5
0.41
0.69

Treatment
Group

1

Normal-ALA

Supplemental
ALA or EPA

Supplemental
ALA or EPA

HED

gms

wt %

energy %

gms

0.3
0.80
1 .45

0.67
1 .78
3.22

0. 1 5
0.33
0.66

0.3
0.66
1 .32

0.67
1 .47
2 .93

0.3
0.82
1 .39

0.67
1 .82
3. 1 0

0. 1 5
0.33
0.66

0.3
0.66
1 .32

0.67
1 .47
2.93

1

Human Equivalent Dose (HED) based on energy% equivalence in a 2000 calorie human diet.

0)
0,

0)
0)

TABLE 3-5
Fatty acid composition of diets used in the High-ALA study 1
Fatty Acid

Control

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

ND

ND

ND

mole %
1 0:0
1 2:0
1 4:0
1 6:0
1 6: 1
1 8:0
1 8: 1 (n-9)
1 8: 1 (n-7)
1 8:2 (n-6)
1 8:3 (n-3)
20:0
20: 1
20:4 (n-6)
20:5 (n-3)
22:0
22.5 (n-3)
22:6 (n-3)

0.07
1 .23
1 .13
23.95
0. 1 7
1 1 .48
38.43
0.57
1 8.29
3.32
0.46
0. 1 3
0. 1 9
0.09
0.22
0. 1 2
0. 1 3

ND

1 .06
1 .16
24.21
0. 1 7
1 1 .45
37.75
0.54
18. 1 9
4.14
0.46
0. 1 3
0. 1 9
0.09
0.22
0. 1 1
0. 1 3

0.07
1 .1 5
1 .1 3
24.01
0. 1 7
1 1 .12
37.04
0.55
1 7.95
5.50
0.45
0. 1 3
0. 1 9
0. 1 0
0.2 1
0. 1 1
0. 1 3

ND

1 .06
1 .09
23.59
0. 1 6
1 1 .06
36.70
0.54
1 7.61
6.90
0.45
0. 1 3
0. 1 8
0.09
0.21
0.1 1
0. 1 3

1 .19
1 .20
24.49
0.17
1 1 .06
38. 1 7
0.57
1 7.94
3.20
0.45
0. 1 3
0. 1 9
0.79
0.21
0.1 1
0. 1 3

1 .1 9
1 .1 9
24. 1 2
0. 1 7
1 1 .08
37.74
0.56
1 7.66
3. 1 8
0.46
0. 1 3
0. 1 9
1 .88
0.2 1
0.1 1
0. 1 2

1 .02
1 .1 1
23. 1 0
0. 1 6
1 1 .21
36.58
0.55
1 7.79
3.39
0.45
0. 1 2
0. 1 9
3.84
0.22
0.1 1
0. 1 3

TABLE 3-5

Continued

Fatty Acid

Control

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

38.60
39.04
22.36
1 8. 1 3
4.23
0.57
0.23

38.25
38.60
23. 1 6
1 7.86
5.30
0.60
0.30

37. 1 0
37.42
25.48
1 8.00
7.48
0.68
0.42

mole %
Total saturated FA
Total MUFA
Total PUFA
Total {n-6)
Total {n-3)
P:S ratio
{n-3):(n-6) ratio
1

2

38.55
39.30
22. 1 6
1 8.49
3.67
0.57
0.20

38.55
38.59
22.85
1 8.38
4.47
0.59
0.24

38. 1 4
37.89
23.97
1 8. 1 4
5.83
0.63
0.32

37.45
37.53
25.02
1 7.79
7.23
0.67
0.41

Powder diets were processed using a modified Bligh and Dyer fatty acid analysis (3 16) (see full description in methods section).
Abbreviations: ND- not detected.
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"----TABLE 3-6
Fatty acid composition of diets used in the Normal-ALA study 1

Fatty Acid

Control

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

0.1 2
1 .79
1 .23
22.87
0.1 5
1 1 .25
40.36
0.59
1 7.67
1 .71
0.47
0.1 4
0.21
0.9 1
0.23
0.1 3
0.1 5

0. 1 3
1 .66
1 .24
22.89
0.1 6
1 1 .32
39 .45
0.57
1 7.59
1 .71
0.47
0.1 4
0.22
1 .95
0.23
0.1 3
0. 1 5

ND

mole %
1 0:0
1 2:0
1 4:0
1 6: 0
1 6: 1
1 8:0
1 8: 1 (n-9)
1 8: 1 (n-7)
1 8:2 (n-6)
1 8:3 (n-3)
20:0
20: 1
20:4 (n-6)
20:5 (n-3)
22:0
22.5 (n-3)
22:6 (n-3)

0.1 5
1 .94
1 .26
22.81
0.1 6
1 0.84
4 1 .25
0.61
1 7.84
1 .73
0.45
0.1 4
0.21
0.1 0
0.22
0.1 3
0.1 7

0.07
1 . 73
1 .26
23.01
0. 1 6
1 1.16
40.35
0.59
1 7.71
2.55
0.46
0. 1 4
0.21
0.1 0
0.22
0. 1 3
0. 1 5

0.1 1
1 .43
1 .20
22.61
0.1 5
1 1 .36
39.67
0.60
1 7.84
3.54
0.48
0.1 4
0.21
0.1 1
0.24
0.1 4
0.1 6

0.1 3
1 .61
1 .28
23.06
0.1 6
1 1 .20
37.51
0.60
1 7.66
5.41
0.46
0.1 4
0.21
0.09
0.22
0.1 3
0.1 5

1 .74
1 .1 7
22.48
0.1 5
1 1 .45
37.68
0.60
1 7.74
1 .72
0.49
0. 1 4
0 .24
3.87
0.24
0.1 4
0. 1 6

TABLE 3-6

Continued

Fatty Acid

Control

ALA-1

ALA-2

ALA-3

EPA-1

EPA-2

EPA-3

37.97
41 .24
20.78
1 7.88
2.90
0.55
0. 1 6

37.93
40.32
2 1 .75
1 7.81
3.94
0.57
0.22

37.56
38.57
23.87
1 7.98
5.89
0.64
0.33

mole %
Total saturated FA
Total MUFA
Total PUFA
Total (n-6)
Total (n-3)
P:S ratio
(n-3) :(n-6) ratio
1

37.67
42. 1 5
20. 1 8
1 8.05
2.14
0.54
0. 1 2

37.91
41 .24
20.86
1 7.92
2.94
0.55
0. 1 6

37.44
40. 56
2 1 .99
1 8.05
3.94
0.59
0.22

37.96
38.40
23.64
1 7.87
5.77
0.62
0.32

Powder diets were processed using a modified Bligh and Dyer fatty acid analysis (31 6) (see full description in methods section).

CJ)

c.o
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overnight and killed via carbon dioxide asphyxiation, followed by blood and tissue
sample collection.

Blood collection
Animals were exsanguinated via cardiac puncture using standard
anticoagulant (dried lithium heparin syringes (Portex brand, Smiths Medical,
Keene, NH) or 3.8% sodium citrate). Collected blood was transferred to
microcentrifuge tubes and inverted. For each experiment, anticoagulated blood
was centrifuged at 660 x g for 4 minutes at room temperature (317). Platelet rich
plasma (PRP) was removed and used for plasma fatty acid analysis. Remaining
packed erythrocytes were suspended in 1 ml 0.9% saline, vortexed, and used for
erythrocyte fatty acid analysis.

Plasma and erythrocyte phospholipid fatty acid analysis
Fatty acids were extracted from plasma and erythrocytes using a modified
Bligh and Dyer analysis (316). Briefly, total lipid extracts were obtained using a
1 :2 (v/v) chloroform/methanol mixture and 1,2-diheptadecanoyl-sn-glycero-3phosphorylcholine added initially as an internal standard. The lipid soluble layer
was separated twice using saturated sodium chloride solution and chloroform
and the lower layer was removed. Removed lipid extracts were dried under an
atmosphere of nitrogen. Dried total lipid was resuspended in a small volume of
chloroform and separated into respective phospholipids, neutral lipids, and free
fatty acids on High Performance Thin-Layer Chromatography plates (silica gel
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60, Merck, Darmstadt, Germany). An 8: 1 (v/v) chloroform/methanol solvent
system was used for HPLC separation. The phospholipid band was scraped
from the origin and saponified with 0.5 mol/L sodium hydroxide in methanol for
15 minutes at 86 ° C. Fatty acids were then methylated using 14% boron
trifluoride in methanol for 10 minutes at 86 ° C. Following acidification with 0.7
mol/L hydrochloric acid in methanol, fatty acid methyl esters were extracted twice
with hexane, dried under nitrogen, resuspended in a small volume of hexane,
and injected onto a Hewlett Packard model 5890 series 1 1 gas chromatograph
(Palo Alto, CA) with flame ionization detector. Fatty acids were separated using
a DB 23, 33m, .25mm diameter capillary glass column packed with fused silica (J
& W Scientific, Folsom, CA). Column temperature was programmed to rise from
160° C at a rate of 3.5 degrees per minute up to a final temperature of 250° C.
Hydrogen was used as the carrier gas. Fatty acid peaks were identified by
comparison to known fatty acid standards (Nu-Chek Prep, Elysian, MN) and peak
area of internal standard 17:0 was used to determine mole percent of sample
peaks.

Identification and selection of clinical trials

This research was designed to evaluate the impact of dietary n-3 PUFA on
fatty acid changes in mice and humans in comparable tissues. While searching
for human data for comparison, the following keywords were used individually
and in various combinations: plasma phospholipids, erythrocyte phospholipids,
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human, omega-3, n-3, fatty acids, ALA, a-linolenic acid, EPA, eicosapentaenoic
acid, DHA, docosahexaenoic acid, supplementation, and intervention. The
search strategy was not designed to be exhaustive, but to provide sufficient data
revealing the overall landscape and general pattern of the effects of dietary n-3
PUFA in humans for comparison to murine effects. Additional sources were
identified from cited references and review articles. Initial searches yielded -60
studies reporting plasma phospholipid changes and -25 studies reporting
erythrocyte phospholipid changes were analyzed.

Papers included in the study

had to report baseline tissue fatty acid compositions and changes in the tissue
post intervention. Dietary interventions ranged from 1 week to 12 months with
most interventions lasting between 1-3 months. The typical human study
involved omega-3 supplementation given in addition to a general diet.
Supplementation of omega-3 fatty acids could be in form of ethyl esters, n-3
PUFA containing capsules, vegetable oils (i.e. flaxseed oil, soybean, canola,
etc .. ) fish and fish oil, so long as the supplemented n-3 PUFA intakes could be
determined. All blood samples for fatty acid analysis had to be collected
following a fast. Both international and domestic studies were included. Studies
were not weighted on the basis of participant number.

Exclusion criteria

included invasive interventions (such as surgery), subjects less than 18 years of
age, and women who were pregnant. After review and exclusion based on the
above factors, roughly 40 studies remained that were used for comparison to
murine data.
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Presentation of the human data
The human data are presented in ascending order along the x-axis by
increasing energy% of the specified supplemented fatty acid, with the y-axis
representing the percent change in a specified plasma or erythrocyte
phospholipid fatty acid as indicated. Difference in pre and post tissue measures
were used to calculate percent change from original values.

Statistical analyses
Phospholipid fatty acid content in plasma and erythrocytes was compared
across treatment groups using one-way analysis of variance (ANOVA), followed
by Fisher's least significant difference post-hoc test to determine significant
differences between groups. Data was considered significant at p < 0.05.
Statistical analysis was performed with SPSS software (Chicago, IL).

3.4

Results

Analysis of intake and weights
Weekly group weight means (in grams) were consistent between groups
and between studies (Figure A-1). Average daily food intake was also

consistent between groups (Figure A-2).
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Changes in phospholipid fatty acids
At the end of the experimental period, fatty acid composition was
determined in plasma and erythrocyte phospholipids for both studies (N-ALA and
H-ALA). Differences in fatty acid composition between experimental groups and
control groups were determined for each PUFA of interest and plotted as percent
change. Murine data was compared to data from archival human clinical trials in
comparable tissues. For each human study, changes in plasma/serum or
erythrocyte phospholipid fatty acids from baseline to post intervention were
determined and, likewise, were plotted as percent change. For graphical
representation, murine and human data representing change in the same tissue
and fatty acid were combined and ordered along the x-axis based on ascending
amounts of supplemented omega-3 fatty acid (in energy%).

Effects of ALA supplementation on changes in plasma and erythrocyte
phospholipki fatty acids
Plasma phospholipid EPA content in N-ALA mice supplemented with
increasing amounts of ALA responded in a dose dependent manner (Table 3-7).
The content of EPA in plasma was relatively low in the control group (0. 1 mol %)
and increased 2, 5, and 8 fold following ALA supplementation of 0.3%, 0.66%,
and 1 .32% of energy, respectively. DHA was modestly higher by 17% and 2 1 %
in the ALA -2 and ALA -3 supplemented groups, respectively. Similar trends
were observed with chan��es in EPA in erythrocyte phospholipids; however,
significant differences were only observed in the in the highest ALA

TABLE 3-7
Plasma phospholipid fatty acid composition by treatment group in the Normal ALA study 1

Fatty Acid

n

=

Control
5

ALA-1
4

ALA-3
5

ALA-2
5

EPA-1
5

EPA-2
4

EPA-3
5

0.4 ± 0.2
29.7 ± 0f
0.7 ± 0.2
8
14.5 ± 0.6
1 1 .7 ± 0.7
0 . 8 ± 0.0
1 8.3 ± 0.1 8
bcd
o.3 ± o.o
0.1 ± 0. 1 8
0 . 1 ± 0. 1
0 . 1 ± 0. 1
0. 1 ± 0. 1 ab
8
1 .4 ± 0. 1
b
1 0.4 ± 0.6
8
1 .7 ± 0.2
ND
ND
0.9 ± 0. 1 d
b
9.0 ± 0.5
c
1 1 .7 ± 0.4
b
30.3 ± 0.7
d
o.4 ± o.o

0.3 ± 0.2
c
28.9 ± 0.5
0.7 ± 0.3
1 5.2 ± 0.7a
1 1 .8 ± 0.9
0.8 ± 0.0
8
1 8.5 ± 0.3
0.2 ± 0 . 1 8
0. 1 ± 0.1 8
0. 1 ± 0 . 1
0.1 ± 0 . 1
8
< 0.1
8
1 .3 ± 0 . 1
8
8.2 ± 0.4
3.2 ± 0.2'
ND
ND
8
1 .3 ± 0.0
b
9.3 ± 0.4
d
1 3.9 ± 0.4
8
28.2 ± 0.7
0.5 ± 0.08

mole % of total fatty acids
1 4:0
1 6:0
16:1
1 8:0
1 8: 1 (n-9)
1 8: 1 (n-7)
1 8:2 (n-6)
1 8:3 (n-6)
1 8:3 (n-3)
20:0
20: 1
20:2
20:3 (n-6)
20:4 (n-6)
20:5 (n-3)
22:4 (n-6)
22.5 (n-6)
22:5 (n-3)
22:6 (n-3)
Total (n-3)
Total (n-6)
(n-3):(n-6) ratio
1

2

0.3 ± 0. 1
8b
27.8 ± 0.7
0.4 ± 0 . 1
1 7.9 ± 1 .2b
1 2.6 ± 0.7
0.8 ± 0.0
8
1 7.9 ± 0.5
0.3 ± 0. 1 cd
8
0.1 ± 0.0
< 0.1
0 . 1 ± 0.0
8b
0. 1 ± 0.0
8
1 . 1 ± 0.0
1 2.8 ± 0.6cd
8
0.1 ± 0.1
8
0.1 ± 0.0
0.2 ± 0.1 b
8
0.2 ± 0.1
8
7.1 ± 0.2
7.6 ± 0.38
cd
32.4 ± 0.6
8
0.2 ± 0.0

0.2 ± 0.0
8
26.6 ± 0.6
0 . 3 ± 0.1
b
1 8.3 ± 0.6
1 2.8 ± 0.5
0.8 ± 0.2
b
21 .3 ± 0.9
8b
0.2 ± 0.0
0 . 1 ± 0.08
0.2 ± 0.0
0.1 ± 0.0
bc
0.2 ± 0. 1
b
1 .7 ± 0. 1
9.7 ± 0.88b
0.2 ± 0.0b
b
0.2 ± 0. 1
b
0.3 ± 0.2
8b
0.3 ± 0.1
8
6.4 ± 0.3
8
7.3 ± 0.3
33.3 ± 0.7'18
0.2 ± 0.08

0.4 ± 0.1
28.7 ± 0.2bc
0.7 ± 0.2
8
1 4.5 ± 0.5
1 1 .7 ± 0.5
0.8 ± 0.0
8
1 8.6 ± 0.5
a1
o.3 ± o.o
b
o.3 ± o.o
0.1 ± 0.0
0.2 ± 0.0
0.2 ± o.obc
8
1 .4 ± 0.0
d
1 2.9 ± 0.2
bc
0.5 ± 0.0
8
0.1 ± 0.0
8
< 0.1
b
o.4 ± o.o
b
8.3 ± 0. 1
b
9.6 ± 0.1
d
33.3 ± o.5 e
b
o.3 ± o.o

0.5 ± 0. 1
bc
28.8 ± 0.4
0.9 ± 0.2
1 4.6 ± 0.68
1 2 . 1 ± 0.7
0.9 ± 0.1
8
1 8.4 ± 0.7
0.3 ± 0.1 bc
b
0.4 ± 0.1
0.2 ± 0.0
0.2 ± 0.0
c
0.2 ± 0.0
b
1 .8 ± 0.1
1 0.8 ± 0.4b
a1
o.8 ± o.o
8
0.1 ± 0.0
8
< 0.1
0.5 ± 0.0c
b
8.6 ± 0.1
b
1 0.4 ± 0. 1
3 1 .3 ± o.ric
c
0.3 ± o.o

0.4 ± 0. 1
c
29.6 ± 0.6
0.8 ± 0. 1
8
1 3.9 ± 0.5
1 2.2 ± 0.7
0.7 ± 0 . 1
8
1 9 . 1 ± 0.3
d
0.4 ± 0.0
0. 1 ± 0.1 8
0.1 ± 0.0
0. 1 ± 0 . 1
0. 1 ± 0.1 8b
1 .2 ± 0. 1 8
1 1 .3 ± 0.7bc
d
o.9 ± o.o
ND
ND
c
0.6 ± o.o
b
8.8 ± 0.3
b
1 0.3 ± 0.3
bcd
3 1 .9 ± 0.6
c
0.3 ± o.o

Results are means ± SEM. Difference in letter superscripts within the same row indicate statistical significance, p <.05.
Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, N D- not detected
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supplemented group (ALA- 3) (Table 3-8). As observed in plasma, DHA levels in
erythrocytes were modestly higher in the ALA-2 and ALA-3 supplemented groups
by 13% and 11 %, respectively.
When the level of ALA in the background diet was doubled (1.2% energy)
(H-ALA), effects on tissue n-3 PUFA content were attenuated (compared to the
N-ALA study) following progressive supplementation of ALA (Table 3-9 and
Table 3-1 0). In plasma phospholipids, the changes in EPA levels were only 2.0
and 2.7 fold higher in the ALA-2 and ALA-3 supplemented groups, while there
were no significant changes in DHA.

Comparison of changes in mouse and human phospholipid fatty acids following
ALA supplementation
When compared to archival human data, the changes observed in the
mouse phospholipid EPA were greater than human changes when the
supplemented doses in the N-ALA groups were matched to human data by
caloric density of supplemented fatty acid (Figure 3-1 and Table 3-1 1 ).
However, the responses observed in the mouse diets containing the higher
background levels of ALA (H-ALA groups) appear to be better correlated with the
human data with respect to changes in EPA levels in both plasma and
erythrocyte phospholipids. ALA had a marginal effect on DHA change in
plasma/serum phospholipids in both mice and humans except for one study,
Ghafoorunissa et al.(318), however, it appeared that this was due to low initial

TABLE 3-8
Erythrocyte phospholipid fatty acid composition by treatment group in the Normal ALA study 1

Fatty Acid

n

=

Control
5

ALA-1
4

ALA-3
5

ALA-2
5

EPA-1
5

EPA-2
5

EPA-3
5

0.3 ± 0.0
29. 9 ± 0.28b
0.4 ± 0.0
1 2.7 ± 1 .2
1 6.0 ± 1 .4
0.9 ± 0. 1
1 2.5 ± 0.8
0.2 ± 0.0
ND
0.2 ± 0.0
b
o.4 ± o.o
b
o.3 ± o.o
c
1 .3 ± 0.1
c
1 6.2 ± 0.8
c
1 .6 ± 0 . 1
c
1 .3 ± 0. 1
8bc
0.5 ± 0.0
c
1 .4 ± 0.1
bc
9.1 ± 0.5
1 2. 1 ± Of
c
32. 1 ± 1 .8
0.4 ± 0.0d

0.3 ± 0.0
bc
30.6 ± 0.5
0.3 ± 0.0
1 2.2 ± 0.1
1 5. 1 ± 0.1
0.8 ± 0.0
1 1 .2 ± 0.3
0.2 ± 0.0
ND
0.2 ± 0.0
b
0.3 ± 0.0
b
0.3 ± O.O
b
1 . 1 ± o.o
b
1 3.2 ± 0.4
d
2.4 ± 0. 1
1 .0 ± 0. 1 b
0.4 ± 0.08b
d
1 .7 ± 0.1
c
8.7 ± 0.2
d
1 2. 8 ± 0.3
b
27. 1 ± 0.3
0.5 ± 0.0

0.2 ± 0.1
c
3 1 . 3 ± 0.6
0.3 ± 0. 1
1 2.0 ± 0.3
1 5.0 ± 0.2
0.8 ± 0.0
1 1 . 1 ± 0.2
0. 1 ± 0.0
ND
0.1 ± 0.0
8
0.2 ± 0.1
0.2 ± 0.1 8
8
1 .0 ± 0.0
8
1 1 .4 ± 0.3
8
4.5 ± 0.2
0.9 ± 0.08
8
0.3 ± 0.1
8
2.4 ± 0.1
bc
8.2 ± 0.2
8
1 5. 1 ± 0.5
8
24.8 ± 0.5
8
0.6 ± 0.0

mole % of total fatty acids
1 4:0
1 6:0
1 6: 1
1 8:0
1 8: 1 (n-9)
1 8: 1 (n-7)
1 8:2 (n-6)
1 8:3 (n-6)
1 8:3 (n-3)
20:0
20: 1
20:2
20:3 (n-6)
20:4 (n-6)
20:5 (n-3)
22:4 (n-6)
22:5 (n-6)
22:5 (n-3)
22:6 (n-3)
Total (n-3)
Total (n-6)
(n-3):(n-6) ratio
1
2

0.3 ± 0.0
30.2 ± 0. 1 8b
0.4 ± 0.0
1 1 .8 ± 0.3
14.7 ± 0.2
0.9 ± 0.1
1 0.6 ± 0.7
0.1 ± 0.0

ND

0.1 ± 0.0
b
0.3 ± 0.0
o.3 ± a.ob
c
1 .3 ± 0 . 1
d
1 8.0 ± 0.8
8
0.3 ± 0.0
1 .6 ± 0 . 1 8
d
0.8 ± 0. 1
0.6 ± 0.1 8
8
7.5 ± 0.2
8
8.4 ± 0.3
8
32.4 ± 0.5
8
0.3 ± 0.0

0.3 ± 0.0
30.0 ± 0.1 8b
0.3 ± 0.0
1 2.0 ± 0.0
1 5.0 ± 0.0
0.9 ± 0.0
1 1 .2 ± 0.2
0.2 ± 0.0
8
0.1 ± 0.0
0.2 ± 0.0
b
0.3 ± 0.0
b
0.3 ± 0.0
c
1 .4 ± 0. 1
00
1 6.6 ± 0.3
8
0.4 ± 0.0
1 .4 ± O.Od8
00
0.1 ± 0.0
8b
0.8 ± 0.0
ab
7.9 ± 0.3
8
9.2 ± 0.2
de
3 1 .5 ± 0.2
b
0.3 ± 0.0

0.3 ± 0.0
8
29.6 ± 0.3
0.3 ± 0.0
1 1 .4 ± 0.1
1 4.6 ± 0.2
0.9 ± 0.0
1 1 .0 ± 0.6
0.1 ± 0.0
b
0.2 ± o.o
0.2 ± 0.0
o.3 ± o.ob
b
o.3 ± o.o
c
1 .2 ± 0. 1
d
1 7.6 ± 0.8
0.5 ± 0 . 1 8
d
1 .4 ± 0.1
cd
0.7 ± 0.1
b
0.9 ± 0.1
bc
8.5 ± 0.3
b
1 0. 1 ± 0.4
de
32. 1 ± 0.3
bc
0.3 ± O.O

0.2 ± 0.0
29.6 ± 0.28
0.4 ± 0.0
1 1 .8 ± 0.4
1 4.7 ± 0.2
0.9 ± 0.0
1 2.3 ± 0.1
0.2 ± 0.0
c
0.3 ± 0.0
0.2 ± 0.0
b
0.3 ± 0.0
b
0.3 ± 0.0
1 .3 ± o.oc
c
1 5.7 ± 0.3
b
o.9 ± o.o
1 .2 ± o.oc
bc
0.5 ± 0.0
1 . 1 ± o.oc
8.3 ± 0.1 bc
1 0.6 ± 0.2bc
3 1 . 1 ± 0.4d
c
0.3 ± o.o

Results are means ± SEM. Different letter superscripts within the same row indicate statistical significance, p <.05.
Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, N D- not detected.
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TABLE 3-9
Plasma phospholipid fatty acid composition by treatment group in the High ALA study 1

Fatty Acid

n=

Control
5

ALA-1
5

ALA-2

ALA-3

5

5

EPA-1
5

EPA-2

EPA-3

0.4 ± 0.2
31 .2 ± 0.2
0.3 ± 0. 1
1 5.2 ± 0.2
9.9 ± 0.3
bc
o.6 ± o.o
1 9.3 ± 0.4
0.3 ± 0.0
a
0 . 1 ± 0. 1
ND
1 .0 ± 0. 1
9.5 ± 0.4b
1 .7 ± 0. 1 °
c
0.9 ± o.o
9.7 ± 0.3
1 2.3 ± 0.3c
b
30. 1 ± 0.5
c
0.4 ± o.o

0.2 ± 0. 1
31 .2 ± 0.4
0.4 ± 0.0
1 5.8 ± 0.3
9.9 ± 0.3
a
0.5 ± o.o
1 8.8 ± 0.2
0.1 ± 0. 1
ND
ND
1 .0 ± 0.0
a
8.1 ± 0.3
3.2 ±
1 . 1 ± 0. 1 d
9.8 ± 0.2
14.1 ± 0.1 d
a
28.0 ± 0.4
o.5 ± o.od

5

5

mole % of total fatty acids
1 4:0
1 6:0
1 6: 1
1 8:0
1 8: 1 (n-9 )
1 8: 1 (n-7 )
1 8:2 (n-6)
1 8:3 (n-6 )
1 8:3 (n-3 )
20:2
20:3 (n-6)
20:4 (n-6)
20:5 (n-3)
22:5 (n-3)
22:6 (n-3)
Total (n-3)
Total (n-6)
(n-3):(n-6) ratio
1
2

0.2 ± 0.1
30.5 ± 0.1
0.3 ± 0.0
1 6. 1 ± 0. 1
1 0.4 ± 0.2
cd
o.6 ± o.o
1 9.4 ± 0.2
0.4 ± 0.0
ND
ND
1 .0 ± 0.0
1 1 .8 ± 0.2de
a
0.3 ± o.o
a
0.4 ± o.o
8.5 ± 0.1
8
9.2 ± 0.1
32.6 ± 0. 1 d
a
0.3 ± o.o

0.3 ± 0. 1
30.9 ± 0.5
0.4 ± 0.0
1 5.5 ± 0.4
9.7 ± 0. 1
0.6 ± o.oab
1 7.9 ± 0.5
0.3 ± 0 . 1
0. 1 ± 0. 1 a
ND
1 .0 ± 0. 1
8
1 2.7 ± 0.3
ab
0.4 ± o.o
a
0.5 ± o.o
9.9 ± 0.4
1 0.8 ± 0.4b
cd
31 .8 ± 0.4
b
o.3 ± o.o

0.3 ± 0. 1
30.6 ± 0.5
0.3 ± 0. 1
1 6 . 1 ± 0.2
9.8 ± 0.3
bcd
o.6 ± o.o
1 9. 1 ± 0.8
0 . 3 ± 0. 1
a
0 . 1 ± 0. 1
< 0.1
1 . 1 ± 0.1
1 0.9 ± 0.5cd
bc
o.6 ± o.o
b
o.5 ± o.o
9.6 ± 0.6
1 0.9 ± 0.6b
bcd
31 .4 ± 0.7
0.4 ± 0.0b

0.4 ± 0. 1
30.6 ± 0.4
0.4 ± 0.0
1 5.5 ± 0.3
9.8 ± 0.4
0.6 ± o.oab
1 9.4 ± 0.4
0.3 ± 0. 1
b
0.4 ± o.o
ND
1 . 1 ± 0. 1
c
1 0.7 ± 0.2
cd
o.8 ± o.o
o.6 ± o.ob
9.4 ± 0.2
1 1 .2 ± 0.2b
31 .5 ± o.4cd
0.4 ± 0.0b

0 . 1 ± 0. 1
31 . 1 ± 0.4
0.4 ± 0.0
1 5.2 ± 0.3
1 0.2 ± 0.2
d
0.1 ± o.o
1 8.7 ± 0.5
0.3 ± 0.0
a
0. 1 ± 0.1
ND
1 .0 ± 0. 1
cd
1 1 . 1 ± 0. 1
d
o.9 ± o.o
b
o.6 ± o.o
9.7 ± 0.3
1 1 .4 ± 0.3bc
31 . 1 ± 0.4bc
0.4 ± 0.0bc

Results are means ± SEM. Different alphabetic superscripts denote statistical significance within each fatty acid, p <.05.
Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, ND- not detected.
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TABLE 3-10
Erythrocyte phospholipid fatty acid composition by treatment group in the High ALA study 1

Fatty Acid

1 4:0
1 6:0
1 6: 1
1 8:0
1 8: 1 (n-9 )
1 8: 1 (n-7)
1 8:2 (n-6)
1 8:3 (n-6)
1 8:3 (n-3)
20: 1
20:2
20:3 (n-6)
20:4 (n-6)
20:5 (n-3)
22:4 (n-6)
22:5 (n-6)
22:5 (n-3)
22:6 (n-3)
Total (n-3)
Total (n-6)
(n-3):(n-6) ratio

n

=

ALA-1
5

ALA-2
5

0.1 ± 0.0
32.0 ± 0.1 ab
0.3 ± 0.0
1 2.3 ± 0.0
1 4.2 ± 0.1 bc
o.9 ± o.ob
1 1 .0 ± 0. 1
0.1 ± 0.0
0.1 ± o.oa
0.3 ± 0.0b
8
0.3 ± 0.0
1 .3 ± o.oc
1 5.2 ± 0.2d
0.5 ± 0.08
1 .2 ± o.od
t
o.5 ±
1 .2 ± 0.08
8.2 ± 0.08
a
1 0.0 ± 0. 1
8
29.3 ± 0. 1
0.3 ± 0.08

0.2 ± 0.0
3 1 .6 ± 0.2 a
0.3 ± 0. 0
1 2.5 ± 0. 1
1 3.8 ± 0.0
0.9 ± o.oab
1 0.9 ± 0.3
0.2 ± 0.0
0.2 ± o.oa
o.3 ± o.ob
d
o.3 ± o.o
c
1 .3 ± o.o
1 5.5 ± 0.2d
0.6 ± 0.08
d
1 .2 ± o.o
0.4 ± 0.08
1 .2 ± 0.08
8.6 ± 0. 1 b
1 0.5 ± 0. 1 b
8
29.4 ± 0. 1
0.4 ± 0.08

mole % of total fatty acids
0.2 ± 0. 1
0.2 ± 0.0
0.2 ± 0.0
32. 1 ± 0. 1 b
32. 1 ± 0.2 b
32.2 ± 0.2 b
0.3 ± 0.0
0.3 ± 0.0
0.3 ± 0.0
1 2.2 ± 0. 1
1 2.2 ± 0.1
1 2.3 ± 0. 1
ab
1 4. 1 ± 0. 1 ab
1 4. 1 ± 0 . 1
1 4.3 ± 0.2bc
b
b
o.9 ± o.ob
o.9 ± o.o
o.9 ± o.o
1 1 .5 ± 0.1
1 1 .0 ± 0.3
1 1 .3 ± 0.3
0.2 ± 0.0
0.2 ± 0.0
0.2 ± 0.0
0.2 ± o.oa
0.3 ± o.oc
o.3 ± o.ob
c
b
0.3 ± o.o
o.3 ± o.ob
o.3 ± o.o
d
cd
o.3 ± a.o e
o.3 ± o.ob
o.3 ± o.o
c
c
1 .3 ± o.o
1 .2 ± o.oc
1 .3 ± o.o
c
c
c
1 3.8 ± 0.2
1 3.8 ± 0.2
1 4.0 ± 0.2
b
c
b
1 .0 ± o.o
1 .5 ± o.o
o.8 ± o.o
1 .0 ± o.oc
1 .0 ± o.oc
1 .0 ± o.oc
cd
c
o.3 ± o.od
o.3 ± o.o
0.3 ± o.o
c
b
c
1 .5 ± o.o
1 .4 ± o.o
1 .6 ± o.o
b
b
8.8 ± 0. 1
8.6 ± 0. 1 b
8.7 ± 0.2
d
c
1 1 .6 ± 0.1
1 1 .8 ± 0.1 d
1 1 .2 ± 0.2
d
cd
27.5
± 0. 1 c
28. 1 ± 0.2
27.9 ± 0.2
bc
b
0.4 ± o.oc
o.4 ± o.o
o.4 ± o.o

o.o

ALA-3
5

EPA-1
5

Control
5

E PA-2
5

0.2 ± 0.0
32.2 ± 0.2 b
0.3 ± 0.0
1 2.3 0.1
1 4.4 ± 0.1 bc
0.9 ± o.oab
1 1 . 1 ± 0.2
0.1 ± 0.0
0. 1 ± o.oa
0.3 ± 0.08
0.3 ± o.oc
1 . 1 ± 0.0b
1 2. 1 ± 0.2b
2.8 ± O.Od
o.8 ± o.ob
0.2 ± o.ob
d
2.0 ± o.o
8.6 ± 0. 1 b
1 3.6 ± 0.28
25.5 ± 0.3b
o.5 ± o.od

±

1 Results are means ± SEM. Different alphabetic superscripts denote statistical significance within each fatty acid, p < .05.
2 Abbreviations: ALA- alpha- linolenic acid, EPA- eicosapentaenoic acid, ND- not detected.

EPA-3
5

0.2 ± 0.0

33.0 ± 0. 1 c

0.3 ± 0.0
1 2.3 ± 0. 1
c
1 4.6 ± 0 . 1
0.8 ± o.o a
1 0.4 ± 0. 1
0.1 ± 0.0
0.1 ± 0.08
0.3 ± 0.08
0.3 ± 0.08
1 .0 ± 0.08
9.8 ± 0.08
4.8 ± 0.28
0.7 ± 0.08
0.2 ± 0.08
2.6 ± 0. 1 8
8.5 ± 0. 1 ab
1 6.0 ± 0.2f
8
22.2 ± 0.2
8
0.7 ± 0.2
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ALA Supplementation by Increasing Energy%

Figure 3-1: Percent change in plasma/serum phospholipid EPA by increasing
ALA supplementation in energy%. Murine data is represented by red bars (N
ALA) or red speckled bars (H-ALA), with human studies intermingled
horizontally. Numerical superscripts correspond to human study descriptions in
Table 3-11.
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TABLE 3-1 1
Human ALA supplementation studies used in Figure 3-1
Vertical bar
in Figure 3-1

Author

Supplemental
Energy% ALA

Citation

1

Sinclair
Seppanen-Laakso
James
Thies
Finnegan
Wallace
Li
Valsta
Mest
Mantzioris
Cunnane
Singer1
Beitz

0.2
0.22,
0.31 ,
0.65
1 . 1 5,
1 .2
1 .2 1 ,
1 .6

(31 9)
(320)
(32 1 )
(322)
(323)
(324)
(325)
(326)
(327)
(328)
(329)
(330)
(331 )

2, 6
3, 4
5

7, 1 1
8
9, 1 4

10
12
13
15
1 6, 1 7
18

4
4.9

6
1 3.6

1 4.7

0.7
0.62
2.89
5.5

1 Supplemental values were the same with 16 representing normolipidemics and 1 7 representing hyperlipidemics.

DHA levels, thus the potential for increase may have been greater than other
human studies (Figure 3-2 and Table 3-1 2).

Effects of EPA supplementation on changes in plasma and erythrocyte
phospholipid fatty acids
Plasma phospholipid EPA content in N- ALA mice supplemented with
increasing amounts of EPA changed significantly in a dose dependent manner
(Table 3-7). The content of EPA in plasma phospholipids was increased 9, 17,
and 32 fold following EPA supplementation of 0.3%, 0.66%, and 1.32% of
energy, respectively. The changes observed in DHA in the lowest EPA
supplemented group (EPA-1) were equivalent to the changes observed in the
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Figure 3-2: Percent change in plasma/serum phospholipid DHA by increasing
ALA supplementation in energy%: (A) Ghafoorunissa (31 8) in yellow and
(B) Excluding Ghafoorunissa, for comparison. Murine data is represented by red
bars (N-ALA) or red speckled bars (H-ALA), with human studies intermingled
horizontally. Numerical superscripts correspond to human study. descriptions in
Table 3-12 (A and 8).
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TABLE 3-12
Human ALA supplementation studies used in Figure 3-2
DHA studies

Vertical bar
in Figure 3-2

Author

Supplemental
Energy% ALA

Citation

A)

1
2, 10
3, 6
4, 5, 8, 9
7
11, 15
12
13, 17
14
16
18
19
20, 21
22

Sinclair
Seppanen-Laakso
James
Ghafoorunissa
Thies
Finnegan
Wallace

0.2
0.22, 0.7
0.31, 0.62
0.6, 0. 7
0.65
1.15, 2.89
1.2
1.21, 5.5
1.6
4.9
6
7.4
13.6
14.7

(319)
(320)
(321)
(318)
(322)
(323)
(324)
(325)
(326)
(328)
(329)
(327)
(330)
(331)

0.2
0.22, 0.7
0.31, 0.62
0.65
1.15, 2.89
1.2
1.21, 5.5
1.6
4.9
6
7.4
13.6
14.7

(319)
(320)
(321)
(322)
(323)
(324)
(325)
(326)
(328)
(329)
(327)
(330)
(331)

B)

1

1
2, 6
3, 4
5
7, 11
8
9 , 13
10
12
14
15
16, 17
18

Li

Valsta
Mantzioris
Cunnane
Mest
Singer 1
Beitz
Sinclair
Seppanen-Laakso
James
Thies
Finnegan
Wallace

Li

Valsta
Mantzioris
Cunnane
Mest
Singer 1
Beitz

Supplemental values were the same with 20A and 16B representing normolipidemics and 21A and 1 7B representing
hyperlipidemics.

84
highest ALA group (ALA-3), with no further increase despite increasing EPA
supplementation 2 and 4 fold (EPA-2, and EPA-3, respectively). Similar trends
were observed with changes in EPA in erythrocytes (Table 3-8), with dose
dependent increases in phospholipid EPA. As observed with the plasma
phospholipid fraction, changes in erythrocyte DHA levels were significantly higher
in the EPA-1 group, but no additional changes were observed in the higher
supplemented EPA groups (EPA-2 and EPA-3).
When the levels of ALA in the background diet doubled (1.2% energy)
(H-ALA), the changes in tissue EPA content were attenuated in comparison to
changes in the N-ALA study (Tables 3-7 and 3-8 versus Tables 3-9 and 3-1 0).
However, tissue levels (in absolute mol%) were comparable following
supplementation irrespective of the background diet (Table 3-8 compared to
Table 3-1 0, and Table 3-7 compared to Table 3-9). Interestingly, no changes in
plasma phospholipid DHA levels were observed with increasing dietary levels of
EPA when compared to the control group (Table 3-9). Changes in erythrocyte
phospholipid DHA levels in the lowest supplemented group increased only 5%
with no further change�s despite increasing levels of EPA in the diet 2 and 4 fold
(Table 3-1 0).

Comparison of changes in mouse and human phospholipid fatty acids following
EPA supplementation
Comparing our results using pure EPA-ethyl esters to human studies in
which a combination of EPA+DHA (in the form of fish or fish oil) is the common
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treatment modality posed a challenge. However, we identified 5 studies with
human subjects that supplemented only EPA and 6 human studies that
supplemented only DHA. The impact of both the EPA only and DHA only studies
on plasma phospholipid EPA (Figure 3-3) and DHA (Figure 3-4) were plotted
together. Results from these studies indicate that EPA is increased when only
EPA is supplemented, but to a lesser extent when only DHA is given. Results
also show that DHA is increased when only DHA is given, but to a lesser extent
when only EPA is given. We used these observations as a guide when
determining how to order human studies in which combination EPA + DHA were
supplemented. When tissue EPA changes were examined, we chose to order
the studies by increasing content of EPA (rather than total n-3 content).
Likewise, when DHA changes were examined, we chose to order the studies by
content of DHA (rather than total n-3 content).
Percent change in plasma phospholipid EPA in both mouse and human
supplementation studiE�s is shown in Figure 3-5. Studies are arranged in
ascending order of the EPA portion of long chain omega-3 fatty acid
supplementation (Table 3-1 4). When compared to human data, the changes
observed in the mouse phospholipid EPA levels were dramatically higher when
the supplemented doses in the N-ALA groups were matched by caloric density.
However, the responses observed in the mouse diets containing the higher
background levels of ALA (H-ALA groups) appear to be better correlated with the
human data with respect to changes in EPA in both plasma and erythrocyte
phospholipids (Figures 3-5 and 3-6).
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TABLE 3-13
Human supplementation studies used in Figure 3-3 and 3-4
Fatty acid

Bars in Figs.
3-3 , 3-4

Author

Supplemental
Energy% ALA

Citation

DHA only

1 ,3
4
6
8
10
12

Jensen
Thies
Vidgren
Grimsgaard
Mori
Buckley

0.06, 0.09
0.23
0.6
1 .3
1 .5
2.2

(332 )
( 322 )
( 333 )
(334 )
( 335 )
( 336 )

EPA only

2
5,7
9
11
13

Driss
James
Grimsgaard
Mori
Buckley

0.07
0.31 , 0.62
1 .4
1 .6
2.2

( 337 )
( 32 1 )
( 334 )
( 335 )
( 336 )
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TABLE 3-14
Human supplementation studies used in Figure 3-5
Vertical bar
in Figure 3-5

Author

Supplemental
Energy% LCPn3

Citation

Total (EPA, DHA, DPA)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41

Jensen
Finnegan
Engstrom
Wallace
Sinclair
Driss
Ghafoorunissa
Wallace
Vidgren
Sinclair
Vidgren
Finnegan
Vognild
Wallace
Engstrom
Vognild
Thies
Hodge
Sinclair
James
Vognild
Sanders
Von Schacky
Kew
Blonk
Vognild
Vognild
James
Cerbone
Von Schacky
Blank
Singer
Laidlaw
Gronn
Stark
Mantzioris
Mantzioris
Gronn
Gibney
Stark
Gronn

0.12 (0.02, 0.1)
0.09 (0.03, 0.06)
0.13 (0.05, 0.08)
0.15 (0.05, 0.1)
0.12 (0.06,0.01, 0.05)
0.07 (EPA only)
0.13 (0.08, 0.05)
0.33 (0.1, 0.23)
0.48 (0.11, 0.32, 0.05)
0.64 (0.12, 0.52)
0.41 (0.14, 0.24, 0.03)
0.4 (0.15, 0.25)
0.53 (0.19, 0.24, 0.1)
0.7 (0.2, 0.5)
0.4 (0.2, 0.2)
0.65 (0.22, 0.33, 0.1)
0.32 (0.23, 0.09)
0.51 (0.27, 0.20, 0.04)
0.94 (0.3, 0.64)
0.31 (EPA only)
0.81 (0.33, 0.45, 0.03)
1.24 (0.34, 0.9)
0.95 ( 0.38, 0.57)
3.01 (0.38, 2.2, 0.43)
0.7 (0.4, 0.3)
1.24 (0.45, 0. 66, 0.13)
1.37 (0.54, 0.77, 0.06)
0.62 (EPA only)
1.66 (0.7, 0.96)
1.92 (0.78, 1.14)
1.3 (0.8, 0.5)
2.29 (0.89, 1.4)
1.8 (1.0, 0.8)
2.1 (1.0, 0.9, 0.2)
1.8 (1.08, 0.72)
1.5 (1.1, 0.4)
1.5 (1.1, 0.4)
2.4 (1.1, 1.1, 0.2)
1.7 (1.2, 0.5)
2.0 (1.2, 0.8)
2.6 (1.2, 1.1, 0.3)

(332)
(323)
(338)
(324)
(339)
(337)
(318)
(324)
(333)
(319)
(333)
(323)
(340)
(324)
(338)
(340)
(322)
(341)
(339)
(321)
(340)
(342)
(343)
(344)
(345)
(340)
(340)
(345)
(346)
(343)
(345)
(330)
(347)
(348)
(349)
(328)
(328)
(348)
(350)
(351)
(348)
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TABLE 3-14
Continued
Vertical bar
in Figure 3-5

Author

Supplemental
Energy% LCPn3

Citation

Total (EPA, DHA, DPA)

42
43
44
45
46
47
48
49

Grimsgaard
Blonk
Von Schacky
Mori
Engstrom
Engstrom
Kew
Buckley

1.4 (EPA only)
2.5 (1.5, 1.0)
3.82 (1.56, 2.29)
1.6 (EPA only)
3.32 (2.0, 1.32)
3.32 (2.0, 1.32)
2.5 (2.1, 0.33, 0.07)
2.2 (EPA only)

(334)
(345)
(343)
(335)
(352)
(352)
(344)
(336)
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Figure 3-6: Percent change in erythrocyte phospholipid EPA by increasing EPA
content of total long chain n-3 supplementation (in energy%). Murine data is
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study descriptions in Table 3-1 5.

92

TABLE 3-15
Human supplementation studies used in Figure 3-6
Vertical bar
in Figure 3-6

Author

Supplemental
Energy% LCPn3

Citation

Total (EPA, DHA, DPA)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Agren
Vidgren
Agren
Vidgren
James
Katan
Sanders
Von Schacky
Wensing
Palozza
James
Katan
Von Schacky
Katan
Palozza
Von Schacky
Palozza
Hagve

0.3 (.09 , .21 )
0.48 (0.1 1 , 0.32, 0.05)
0.38 (0.13, 0.25)
0.41 (0. 1 4, 0.24, 0.03)
0.31 (EPA only)
0.40 (0.3 1 , 0.06, 0.03)
1 .24 (0.34, 0.9)
0.95 (0.38, 0.57)
0.75 (0.49, 0.26)
1 .02 (0.57, 0.45)
0.62 (EPA only)
0.83 (0.63, 0.1 3, 0.07)
1 .92 (0.78, 1 .1 4)
1 .23 (0.94, 0.1 9 , 0.01)
2.08 (1 . 1 0, 0.98)
3.85 (1 .56, 2.29)
3.1 4 (1 .67, 1 .47)
2.6 (1 .7, 0.9)

(353)
(333)
(354)
(333)
(321)
(355)

(342 )

(343)
(356)
(357)
(32 1 )
(355)
(343)
(355)
(357)
(343)
(357)
(358)
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3.5

Discussion
In 1932, Max Kleiber, pioneer in the field of animal energetics, presented

an equation that simplified the understanding of interspecies differences in
metabolic rate: Y= ax¾, where Y is the metabolic rate in kcal, x is bodyweight in
kilograms, a is the proportionality constant, and ¾ is the scaling exponent and
the slope of the regression line depicting this relationship (277-279). Further
characterization and development of interspecies comparison as it relates to
nutrient intake was present by Rucker (300, 301) and Storm (300), who
emphasized the need for attention to interspecies metabolic rate differences
when comparing vitamin and mineral requirements between species. The
current study is a product of these questions in light of n-3 fatty acid research
using the rodent model. Historic attempts to linearize and explain interspecies
differences are applicable not only to metabolic rate and vitamin andmineral
requirements, but other nutrient components as well. Here, we have tested a
simple, hypothetical dosing model for adding supplemental n-3 fatty acids to
rodent diets on the basis of energy %. This model was created based on
theoretical conclusions of interspecies comparisons previously presented
(Chapter 2).
The driving force of this evaluation is a calculated attempt to achieve
supplemental doses in the rodent model that offer better predictive value for
human endpoints. Research examining the relationship between n-3 fatty acid
supplementation and cancer outcomes is one example where better predictive
value is needed. Currently, there exists a disparity between the outcomes
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achieved in human clinical trials with n-3 fatty acids and cell culture or animal
model studies in cancer research (95). For example, while animal studies
support a role for n-3 fatty acid effect on colorectal cancer, some human studies
imply an association (165-167), while others do not (359, 360). We believe that
one explanation for this inconsistency may be the difference in the amounts of n3 fatty acids that are supplemented in animal model experiments versus the
doses that are given in clinical trials. For example, a literature search of recent
animal model studies supplementing n-3 fatty acids reveals that when the animal
doses are translated to human doses on the basis of energy %, n-3
supplementation ranged from 6-90 gms/day (259-276, 361). Doses from the
majority of these studies would not be compatible with reasonable daily human
consumption, and therefore, results observed from these studies may not be
reproducible in humans.
In the current study, we designed background diets that contained long
chain PUFA (both n-3 and n-6) that are present in the typical human diet in order
to compare murine results to archival human trial data. We also used
supplemental doses that were a reasonable representation of intake that could
be achieved in humans (670 mg - 3.2 gms/d on the basis of energy%,
Table 3-4). We found that in C57BL/6J mice at these supplemental levels, both
ALA and EPA significantly increased EPA in both plasma and erythrocytes, with
EPA supplementation having a greater effect on phospholipid EPA than ALA
supplementation. DHA, on the other hand, was less influenced by either ALA or
EPA supplementation and generally increased only when DHA was
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supplemented (Figures 3-2 and 3-4). In addition, it was found that DHA did not
increase interminably in response to increasing supplemental DHA doses
(Figure 3-7). These findings are consistent with animal studies in which
ALA supplementation increases tissue DHA levels only when ALA content is not
appreciable in the control diet used for comparison, and further increases in
ALA dose do not result in dose dependent increases in DHA (ex: (362)).
We have shown that when n-3 fatty acids are supplemented to rodent
diets on the basis of energy%, the effect in mice is greater than the effect in
humans at comparable supplemental energy% (N-ALA background). There are
several possible reasons for this finding. Hulbert, et al., examined tissues from
animals over a broad range of size and found that accumulation of
polyunsaturated fatty acids in several tissues was inversely related to body mass,
suggesting that tissue from small animals (ex:rodents) would have a higher
tissue unsaturation index than the same tissue from larger animals (ex:humans)
(254). This may explain why the H-ALA background produced changes that
better matched archival human changes than the N-ALA background (based on
total tissue unsaturation). Differences in tissue fatty acid changes may also
reflect a difference in the capacity for enzymatic conversion of ALA to long chain
metabolites between rodents and humans (363). The discrepancy between
rodent and human tissue changes may also suggest that doses derived on the
basis of caloric density do not produce human equivalent effects. However, if
these low supplemental doses produce changes that are greater than human
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TABLE 3-16
Human supplementation studies used in Figure 3-7
Vertical bar
in Figure 3-7

Author

Supplemental
Energy% LC Pn3

Citation

Total (EPA, DHA, DPA)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Sinclair
Ghafoorunissa
Jensen
Finnegan
Engstrom
Jensen
Thies
Jensen
Wallace
Engstrom
Hodge
Thies
Wallace
Vidgren
Vognild
Finnegan
Blonk
Vidgren
Vognild
Kew
Mantzioris
Mantzioris
Vognild
Wallace
Gibney
Blonk
Sinclair
Von Schacky
Vidgren
Sinclair
Vognild
Stark
Vognild
Laidlaw
Stark
Sanders
Gronn
Cerbone
Blonk
Gronn
Gronn
Von Schacky

0. 1 2 (0.06,0.01 0.05)
0. 1 3 (0.08, 0.05)
0.06 (DHA only)
0.09 (0.03, 0.06)
0. 1 3 (0.05, 0.08)
0.09 (DHA only)
0.32 (0.23, 0.09)
0. 1 2 (0.02, 0. 1 )
0. 1 5 (0.05, 0. 1 )
0.4 (0.2, 0.2)
0.51 (0.27, 0.20, 0.04)
0.23 (DHA only)
0.33 (0. 1 , 0.23)
0.41 (0. 1 4, 0.24, 0.03)
0.53 (0. 1 9, 0.24, 0. 1 )
0.4 (0. 1 5, 0.25)
0. 7 (0.4, 0.3)
0.48 (0. 1 1 , 0.32, 0.05)
0.65 (0.22, 0.33, 0. 1 )
2.5 (2. 1 , 0.33, 0.07)
1 .5 (1 . 1 , 0.4)
1 .5 (1 . 1 , 0.4)
0.81 (0.33, 0.45, 0.03)
0. 7 (0.2, 0.5)
1 .7 ( 1 .2, 0.5)
1 .3 (0.8, 0.5)
0.64 (0. 1 2, 0.52)
0.95 ( 0.38, 0.57)
0.6 (DHA only)
0.94 (0.3, 0.64)
1 .24 (0.45, 0.66, 0. 1 3)
1 .8 ( 1 .08, 0.72)
1 .37 (0.54, 0. 77 0.06)
1 .8 ( 1 .0, 0.8)
2.0 { 1 .2, 0.8)
1 .24 {0.34, 0.9)
2.1 {1 .0, 0.9, 0.2)
1 .66 {0.7, 0.96)
2.5 { 1 .5, 1 .0)
2.4 (1 .1 , 1 . 1 , 0.2)
2.6 {1 .2, 1 . 1 , 0.3)
1 .92 {0.78, 1 . 1 4)
I

I

(339)
(31 8)
(332)
(323)
(338)
(332)
(322)
(332)
(324)
(338)
(34 1 )
(332)
(324)
(333)
(340)
(323)
(345)
(333)
(340)
(344)
(328)
(328)
(340)
(324)
(350)
(345)
(31 9)
(343)
(333)
(339)
(340)
(349)
(340)
{347)
{351 )
(342)
{348)
(346)
{345)
{348)
{348)
(343)
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TABLE 3-16
Continued
Vertical bar
in Figure 3-7

Author

Citation

Total (EPA, DHA, DPA)

A (cont'd).

B.

Supplemental
Energy% LCPn3

43
44
45
46
47
48
49
50

Grimsgaard
Engstrom
Engstrom
Singer
Mori
Buckley
Kew
Von Schacky

1.3 (DHA only)
3.32 (2.0, 1.32)
3.32 (2.0, 1.32)
2.29 (0.89, 1.4)
1.5 (DHA only)
2.2 (DHA only)
3.01 (0.38, 2.2, 0.43)
3.82 (1.56, 2.29)

(334)
(352)
(352)
(330)
(335)
(336)
(344)
(343)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Katan
Payet
Katan
Katan
Agren
Vidgren
Agren
Wensing
Vidgren
Palozza
Von Schacky
Vidgren
Sanders
Hagve
Palozza
Von Schacky
Palozza
Von Schacky

0.40 (0.31, 0.06, 0.03)
0.09 (0.008, 0.08)
0.83 (0.63, 0.13, 0.07)
1.23 (0.94, 0.19, 0.01)
0.3 (.09, .21)
0.41 (0.14, 0.24, 0.03)
0.38 (0.13, 0.25)
0.75 (0.49, 0.26)
0.48 (0.11, 0.32, 0.05)
1.02 (0.57, 0.45)
0.95 (0.38, 0.57)
0.6 (DHA only)
1.24 (0.34, 0.9)
2.6 (1.7, 0.9)
2.08 (1.10, 0.98)
1.92 (0.78, 1.14)
3.14 (1.67, 1.47)
3.85 (1.56, 2.29)

(355)
(364)
(355)
(355)
(353)
(333)
(354)
(356)
(333)
(357)
(343)
(333)
(342)
(358)
(357)
(343)
(357)
(343)

changes in similar endpoints, we feel confident that the differences between
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mouse and human changes in this study are conservative compared to the
differences that can be expected from supplemental n-3 studies in the general
literature with even greater doses.
Dosing on the basis of energy% represents a reasonable method for the
addition of n-3 fatty acids to rodent studies. Without a current standard for
supplemental dosing strategies, this study is unique in that it sheds light on the
gross over-estimation of human response that can be expected from animal
studies in which large n-3 doses are supplemented. It is also unique in that
mouse changes were shown to exceed human tissue changes even when long
chain PUFA (n-3 and n-6) were present in the diet. This further suggests that
typical rodent studies, in which long chain PUFA are not present in the
control/background diet, can be expected to overestimate human endpoint
effects.

3.6

Conclusions
While the use of energy% as a dosing model does not precisely predict

changes in human endpoints, we feel that it establishes a guideline for dosing
that considers interspecies variation inherent in dietary research using animal
models. In order for rodent studies using supplemental n-3 doses to be
meaningful, we must reevaluate how doses are selected. It is our hope that by
offering this vivid comparison between effects in rodents and humans at known
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supplemental levels, we are offering both a point of reference and a justification
for change.

SUMMARY AND CONCLUSIONS

4

1 01

The establ ishment of a "human equivalent dose" model for n-3 fatty acid
supplementation is necessary to validate both past and future fatty acid research
using animal models. Human equivalent dosing offers a useful pre-clinical
screening tool for establishing n-3 fatty acid effects in animal models prior to
investment in larger and more expensive human clinical trials. However, attention
to dosing "equivalence" is currently not standard in animal studies supplementing
n-3 fatty acids. In the present study, we have presented a simple and unique
model for supplementing n-3 fatty acids to rodent diets on the basis of energy%.
We compared the effects of n-3 fatty acid supplementation on plasma and
erythrocyte phospholipid fatty acids in C57BL/6J mice and archival human
studies measuring the same endpoints. This allowed us to test the ability of
energy% dosing to predict expected changes in humans. Comparison between
changes in rodent and human tissues at the same energy% of supplemented
ALA and EPA showed that murine changes in both plasma and erythrocyte
phospholipid fatty acids exceeded changes observed in humans. In addition,
increasing ALA content in the background diet produced changes in both tissues
that were more comparable to results seen in humans. While energy% did not
precisely predict changes in human endpoints, dosing based on energy%
represents a decrease from supplemental levels that are typically used in rodent
.

.

studies and therefore offers an improvement to common rodent supplemental n-3
fatty acid doses. We believe that energy% dosing offers a more conservative

1 02
estimate of human endpoint changes than doses that are currently in use.
Future research is necessary to refine with precision a mathematical model that
will more closely predict changes in human endpoints. It is our hope that by
providing these comparisons we will encourage fatty acid dosing that is based on
a calculated comparison between humans and animal models.

1 03
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Fi gure A-1: Weekly weights and ending weight of mice in (a) Normal-ALA study
and (b) High-ALA study. At the start of treatment period, mice in the
Normal- ALA study were 1 7 days older than the mice in the High ALA study.

1 41

A.
- 6

EftS

•

5

S 4

•

• Control
• ALA-1
ALA-2
X ALA-3
X EPA-1
• EPA-2
+ EPA-3

�

ftS

.E

2

"C

0 1
0

0

4

14

9

19

Day of Treatment

8.
- 5

E

• Control
• ALA-1
ALA-2
X ALA-3
X EPA-1
e EPA-2
+ EPA-3

4

- 3
�

J!C:

2

"C

1

0
0

0

0

5

10
Day of Treatment

15

20
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"Failure is not the falling down- but the staying down."

- John Keats

"I can't go to school to fulfill my dream of becoming an engineer, but I will be the
best printer that I can be."
- Harry Wills (my grandfather)
"I have fought the good fight, I have finished the race, I have kept the faith."

II Timothy 4:7

"It is not that we think that we can do anything of lasting value by ourselves. Our
only power and success come from God."
II Corinthians 3:5

